


EP300 Selectively Controls the Enhancer Landscape of *MYCN*-Amplified Neuroblastoma



Adam D. Durbin^{1,2,3,4}, Tingjian Wang⁵, Virangika K. Wimalasena⁵, Mark W. Zimmerman¹, Deyao Li⁵, Neelesh V. Dharia^{1,2,3}, Luca Mariani⁶, Noha A.M. Shendy⁴, Stephanie Nance⁴, Anand G. Patel⁷, Ying Shao⁸, Maya Mundada⁴, Lily Maxham⁸, Paul M.C. Park⁵, Logan H. Sigua⁵, Ken Morita¹, Amy Saur Conway¹, Amanda L. Robichaud¹, Antonio R. Perez-Atayde⁹, Melissa J. Bikowitz^{10,11}, Taylor R. Quinn¹², Olaf Wiest¹², John Easton⁸, Ernst Schönbrunn^{10,11}, Martha L. Bulyk^{3,6,13}, Brian J. Abraham⁸, Kimberly Stegmaier^{1,2,3}, A. Thomas Look^{1,2}, and Jun Qi^{5,14}



ABSTRACT

Gene expression is regulated by promoters and enhancers marked by histone H3 lysine 27 acetylation (H3K27ac), which is established by the paralogous histone acetyltransferases (HAT) EP300 and CBP. These enzymes display overlapping regulatory roles in untransformed cells, but less characterized roles in cancer cells. We demonstrate that the majority of high-risk pediatric neuroblastoma (NB) depends on EP300, whereas CBP has a limited role. EP300 controls enhancer acetylation by interacting with TFAP2 β , a transcription factor member of the lineage-defining transcriptional core regulatory circuitry (CRC) in NB. To disrupt EP300, we developed a proteolysis-targeting chimera (PROTAC) compound termed “JQAD1” that selectively targets EP300 for degradation. JQAD1 treatment causes loss of H3K27ac at CRC enhancers and rapid NB apoptosis, with limited toxicity to untransformed cells where CBP may compensate. Furthermore, JQAD1 activity is critically determined by cereblon (CRBN) expression across NB cells.

SIGNIFICANCE: EP300, but not CBP, controls oncogenic CRC-driven transcription in high-risk NB by binding TFAP2 β . We developed JQAD1, a CRBN-dependent PROTAC degrader with preferential activity against EP300 and demonstrated its activity in NB. JQAD1 has limited toxicity to untransformed cells and is effective *in vivo* in a CRBN-dependent manner.

INTRODUCTION

Gene transcription is controlled by networks of epigenetic regulators and master transcription factors (TF; reviewed in refs. 1, 2). These proteins form complexes that modulate DNA accessibility and establish epigenetic marks to control the activity of specific gene enhancers and promoters (2, 3). Gene enhancers are required to control the mRNA expression of the genes that establish cell fate (4). These identity-defining processes are dysregulated in disease states, including cancer, by the altered regulation of transcription, often through selection for mutations in epigenetic regulatory proteins (2, 5–8).

The establishment of cell identity and fate requires a high level of expression of key lineage-related master TFs (4, 9). Master TF loci are typically associated with enhancer elements marked by extensive stretches of acetylation on histone H3 lysine 27 (H3K27ac), termed “super-enhancer” or “stretch-enhancer” (SE) elements (10, 11). H3K27ac is catalyzed by the activity of two paralogous enzymes, the E1A-binding protein (EP300, KAT3B) or the CREB-binding protein (CREBBP,

CBP, KAT3A; refs. 12, 13). These two enzymes share a large degree of sequence homology, and both contain multiple homologous domains, including kinase-inducible domain interacting (KIX) domains, histone acetyltransferases (HAT), and bromodomains (14). Each protein can catalyze H3K27ac and acetylate lysine residues on many other proteins (15). Given the extensive homology between these related HAT enzymes, many review articles refer to them as one unit—EP300/CBP—and all available inhibitors of their HAT and bromodomains cross-react with both enzymes with nearly identical K_d values (13, 16–19).

Various studies have suggested that EP300 and CBP play overlapping but distinct roles in the regulation of cell survival. Germline loss of EP300 or CBP results in murine embryonic lethality with distinct phenotypes (20). Furthermore, CBP is required for self-renewal, while EP300 is required for the differentiation of hematopoietic stem cells (21). Somatic mutations of either EP300 or CBP are found in a variety of malignancies (22), and in CBP-mutated tumor cells, loss of EP300 is synthetic lethal (23). Chromatin

¹Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. ²Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts. ³The Broad Institute of MIT and Harvard, Cambridge, Massachusetts. ⁴Division of Molecular Oncology, Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. ⁵Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. ⁶Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. ⁷Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. ⁸Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee. ⁹Department of Pathology, Boston Children's Hospital, Boston, Massachusetts. ¹⁰Drug Discovery Department, Moffitt Cancer Center, Tampa, Florida. ¹¹Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida. ¹²Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana. ¹³Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. ¹⁴Department of Medicine, Harvard Medical School, Boston, Massachusetts.

Note: Supplementary data for this article are available at Cancer Discovery Online (<http://cancerdiscovery.aacrjournals.org/>).

A.D. Durbin and T. Wang contributed equally to this article.

Corresponding Authors: Adam D. Durbin, St. Jude Children's Research Hospital, DTRT-5062F, 262 Danny Thomas Place, Memphis, TN 38112. Phone: 901-595-7711; E-mail: adam.durbin@stjude.org; Kimberly Stegmaier, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215. Phone: 617-632-4438; E-mail: Kimberly_stegmaier@dfci.harvard.edu; A. Thomas Look, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215. Phone: 617-632-5826; E-mail: thomas_look@dfci.harvard.edu; and Jun Qi, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215. Phone: 617-632-6629; E-mail: jun_qi@dfci.harvard.edu

Cancer Discov 2022;12:730-51

doi: 10.1158/2159-8290.CD-21-0385

This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 International (CC BY-NC-ND).

©2021 The Authors; Published by the American Association for Cancer Research

immunoprecipitation coupled to high-throughput sequencing (ChIP-seq) studies have identified largely overlapping but distinct binding of EP300 and CBP genome-wide, indicating that these two proteins may function differently by regulating the enhancers of distinct genes (24, 25). However, many studies interrogating EP300 and CBP have relied on genetic disruption or mRNA depletion of each gene, which does not permit a time-associated analysis, or alternatively have relied on the use of inhibitors with nonselective activity against both enzymes (13, 16–19). The derivation of pharmacologic inhibitors targeting only one of these enzymes has thus been limited by the homology between these proteins (13, 18). This has fundamentally limited our ability to rapidly dissect independent mechanisms regulated by each individual enzyme in cells.

One group of newly developed pharmacologic compounds has been used to induce targeted protein degradation mediated by E3 ligase receptor proteins and their small-molecule binders. These include the E3 ligase receptor protein Cereblon (CRBN) and its binding molecules, the phthalimides (thalidomide, lenalidomide, and pomalidomide, referred to as IMiDs—immunomodulatory drugs; ref. 26). Heterobifunctional molecules termed proteolysis-targeting chimeras (PROTAC) induce ligand-dependent target protein degradation by recruitment of target proteins to the proteasome. PROTAC E3-binding heterobifunctional small molecules have been validated for a variety of targets including BRD4, FKBP12, $ERR\alpha$, RIPK2, BRD9, and p38 MAPK, among others (reviewed in refs. 27, 28). By catalyzing the formation of a ternary complex involving an E3 ligase receptor, a protein of interest, and a small molecule, PROTACs may yield enhanced substrate specificity (29).

Here, we used functional and chemical genomics to show that EP300, but not CBP, is typically required for establishment of H3K27ac at essential gene enhancers in the high-risk pediatric cancer neuroblastoma (NB). We identify that EP300 has an enhancer-regulating dependency in NB and is recruited to DNA by interactions with the AP2 TF TFAP2 β , a member of the lineage-defining core regulatory circuitry (CRC) of NB. In contrast, CBP is dispensable for the malignant phenotype in most cases and does not interact with TFAP2 β . Using a chemical biology strategy, we synthesized a novel PROTAC degrader, called JQAD1, which displays strong selectivity for EP300, and use this chimeric small molecule to demonstrate a time-dependent loss of EP300, enhancer acetylation, and transcriptional output in NB cells both *in vitro* and *in vivo*. In contrast to catalytic inhibition, this degrader molecule rapidly drives NB apoptotic cell death associated with MYCN downregulation. Further, it has limited toxicity to untransformed cells *in vivo* while causing growth delay of NB tumor xenografts. Finally, we demonstrate that enhanced dependency on EP300 or CBP is found across numerous cancer lineages and confirm that the mechanism of degrader function is highly dependent on expression of CRBN, providing a foundation that will enable the study of EP300-selective and other degraders in multiple distinct cellular contexts. Thus, this study identifies a critical role for EP300 in regulating the enhancer and transcriptional landscapes of high-risk NB through physical interactions with the oncoprotein MYCN and TFAP2 β , members of the CRC.

RESULTS

EP300 Is Required for High-Risk NB Growth

Previously, we showed that high-risk NB selectively requires a group of 147 genes for survival (9). One of these genes encodes the histone acetyltransferase enzyme EP300, but the gene encoding its paralog, CBP, is not required, which is surprising because EP300 is often redundant with CBP (13). Both EP300 and CBP acetylate the Lys-27 residue of histone H3 (H3K27ac), which is a mark associated with active gene transcription (9, 13). We were intrigued that EP300 appeared to be uniquely required in NB compared with CBP and therefore sought to investigate the relative expression and dependency of these two genes across a panel of representative NB cell lines. First, we examined the relative dependency of EP300 or CBP in 19 high-risk NB cell lines using the DepMap exome-wide CRISPR–Cas9 deletion dataset (30). This demonstrated that most high-risk NB cell lines require EP300 for cell growth (Fig. 1A). Interestingly, in four of the cell lines with a high level of dependency on EP300, we also observed dependency on CBP, indicating that each protein was essential (Fig. 1A). Four cell lines were not dependent on either EP300 or CBP, potentially indicating redundancy of these two acetyltransferases in these cell lines (Fig. 1A). To extend these findings, we performed CRISPR–Cas9-mediated knockout of *EP300* and *CBP* in two *MYCN*-amplified NB cell lines, Kelly and BE2C (Fig. 1B; Supplementary Fig. S1A). Although both EP300 and CBP are expressed in these two cell lines, only loss of EP300 caused a profound reduction of H3K27ac expression levels, while loss of CBP had a more minor effect, indicating that in these cell lines, most enhancers and promoters rely on EP300 to catalyze H3K27ac. Further, expression of *MYCN*, which is a well-known dependency in *MYCN*-amplified NB, was almost completely dependent on EP300 and much less so on CBP (Fig. 1B; Supplementary Fig. S1A). Accordingly, CRISPR–Cas9-mediated deletion of EP300 markedly reduced colony formation in each cell line, while CBP loss did not (Fig. 1C). The residual colonies formed by EP300 CRISPR knockout cells did not express GFP, which was coexpressed in the vector containing the guide RNA, indicating that they represent cells that were not infected with the vector containing EP300-targeted guide RNAs.

Analysis of *EP300* and *CBP* mRNA expression in primary NB tumors revealed a positive correlation (Supplementary Fig. S1B). Further, analysis of publicly available sequencing data in primary NB tumors demonstrated that while inactivating mutations in *EP300* or *CBP* did occur in human high-risk NB, they were extremely rare (31). By Western blotting, EP300 and CBP levels were generally correlated across a panel of NB cell lines (Supplementary Fig. S1C). Analysis of cancer cell lines in the Cancer Cell Line Encyclopedia (CCLE) proteomics and mRNA expression datasets also showed correlated expression levels of EP300 and CBP at both the RNA and protein levels, including the cell lines from patients with NB (in red), indicating that these findings pertain to multiple tumor lineages (Supplementary Fig. S1D and S1E).

To test our genetic findings using small-molecule probes, we next performed colony formation assays of NB cells using known EP300 and CBP inhibitors that are nonselective between these two proteins. This included two inhibitors




Figure 1. EP300, but not CBP, is required for NB cell growth. **A**, Heat map of probability of dependency on NB cell lines ($n = 19$) in the DepMap 20Q2 data release demonstrates that most NB cell lines depend on EP300 (darker red color) compared with only few requiring CBP. **B**, Kelly cells stably expressing Cas9 were infected with single-guide RNAs (sgRNA) targeting EP300 (EP300-1,2), CBP (CBP-1,2), or controls (ch2.2, LACZ) for five days, prior to Western blotting to the noted targets. Data are representative of three independent sgRNA infections and lysates. **C**, Colony formation assays were performed following sgRNA infection as in **C** in Kelly and BE2C cells. Cells were cultured for 10 days after infection. $n = 3$ independent replicates per cell line, per treatment. *, $P < 0.05$. Bars, SEM. **D**, Kelly NB cells were treated in colony formation assays with a range of concentrations of the EP300/CBP combined inhibitors C646, CBP30, and A485. $n = 3$ independent replicates per cell line, per treatment. Bars, SEM. See also Supplementary Fig. S1.

targeting the EP300 and CBP HAT domain, A485 and C646 (18, 19), and one targeting the bromodomain, CBP30 (16). In multiple NB cell lines, the most potent compound in reducing NB colony formation was the HAT domain inhibitor A485 (Fig. 1D; Supplementary Fig. S1F–S1H). Nonspecific inhibition of both EP300 and CBP with A485 caused G₁ cell-cycle arrest within 24 hours (Supplementary Fig. S1I–S1K), similar to the effects of knockout of EP300, but not CBP

(Supplementary Fig. S1L and S1M). After seven days, A485 treatment led to global loss of the H3K27ac modification, loss of MYCN expression, induction of cleaved caspase 3 and PARP1, and increased cells in the sub-G₁ peak—all indicative of apoptotic cell death (Supplementary Fig. S1N and S1O). Although both cell-cycle progression and cell survival are impaired by inhibition of the HAT activity of both EP300 and CBP, our genetic studies indicate that this is due to a

dependency on EP300, not CBP, for the growth and survival of most *MYCN*-amplified NB cell lines.

EP300 Facilitates Adrenergic NB CRC-Driven Transcription through Binding to TFAP2 β

Next, we sought to determine the mechanism by which EP300, but not CBP, was required for growth of *MYCN*-amplified NB cell lines. Previously, we demonstrated that CRC TFs are critically important in determining cell fate in NB and are marked and regulated by H3K27ac-marked super-enhancers (9, 32, 33). This analysis uncovered that the master TFs of the adrenergic NB subtype include *HAND2*, *ISL1*, *PHOX2B*, *GATA3*, *TBX2*, and *ASCL1*. Thus, we sought to understand the mechanism by which EP300 collaborates with the NB CRC-driven gene expression program. We began by using the STRING database to perform an interaction analysis of all expressed nuclear NB dependency proteins (34). This demonstrated that EP300 was found in a densely interacting network of proteins enriched for CRC TFs (Fig. 2A; refs. 9, 35). To understand the genome-wide binding patterns of EP300 and CBP, we performed ChIP-seq experiments using antibodies recognizing EP300 and CBP in two separate *MYCN*-amplified NB cell lines, BE2C and Kelly (Fig. 2B; Supplementary Fig. S2A). The majority of sites genome-wide bound by EP300 were also bound by CBP, based on genome-wide scatter plot analysis (Fig. 2B; Supplementary Fig. S2A). Intriguingly, a small number of sites were preferentially bound by either EP300 or CBP (Fig. 2B; Supplementary Fig. S2A). Next, to examine the importance of EP300 and CBP in regulating gene expression programs in NB cells, we assayed the degree of colocalization of EP300 and CBP with the targets of the previously defined NB CRC TFs and H3K27ac (Fig. 2C; Supplementary Fig. S2B). Genome-wide heat map analysis demonstrated that both EP300 and CBP displayed a similar pattern of binding as each of the CRC TFs (Fig. 2C; Supplementary Fig. S2B). Previously, we identified that some of the most heavily bound sites marked by H3K27ac in NB cells included the CRC TF loci (9). Focused evaluation of EP300 and CBP binding at the loci encoding the CRC TFs demonstrated colocalization of EP300 with CRC TFs (Fig. 2D; Supplementary Fig. S2C, red tracks). CBP, however, was minimally enriched at these loci (Fig. 2D; Supplementary Fig. S2C, green tracks). These data indicate that EP300, but not CBP, is preferentially localized at sites that control the expression of adrenergic CRC genes in NB cells (9).

Both EP300 and CBP lack sequence-specific DNA-binding activity and require association with a DNA-binding factor to achieve locus-specific binding (36). Thus, we sought to identify how EP300 is targeted to chromatin loci associated with enhancers of the CRC. To identify proteins involved in EP300 recruitment to DNA in NB cells, we performed a motif enrichment analysis of the top 500 peaks bound specifically by either EP300 or CBP in Kelly and BE2C cells. Consistent with prior evidence indicating that EP300 proteins form interactions with several TFs to nucleate higher-order enhanceosome structures (37), this analysis demonstrated enrichment for several TF consensus binding motifs preferentially associated with EP300 and/or CBP binding (Fig. 2E and F; Supplementary Fig. S2D and S2E).

Two motifs were selectively enriched under EP300-bound peaks in both cell lines, corresponding to consensus binding sequences for the TFs *GATA3* and *TFAP2 β* (Fig. 2E and F; Supplementary Fig. S2D and S2E). To validate that these TFs associate with H3K27ac-marked chromatin, we next performed coimmunoprecipitation (co-IP) of H3K27ac from nuclear extracts of Kelly and BE2C cells, followed by mass spectrometry of the isolated protein. As expected, in both Kelly and BE2C cells, we detected peptides corresponding to EP300 and CBP that coimmunoprecipitated with H3K27ac. This experiment also identified that four TFs, including *GATA3* and *TFAP2 β* , physically interact with H3K27ac-marked nucleosomes in both cell lines (Supplementary Table S1; Supplementary Fig. S2F). *GATA3* is a known member of the CRC of high-risk NB cells (9, 32). Previously, we and others identified *TFAP2 β* as a possible CRC member, because it is a TF and a growth dependency in NB cells that is commonly regulated by a super-enhancer (9, 33, 35); however, we could not prove this because suitable antibodies for ChIP-seq were not available to determine sites of chromatin binding. Using new antibodies against *TFAP2 β* , we performed ChIP-seq for *TFAP2 β* binding, and identified that it binds to the super-enhancers and regulates other members of the CRC (Fig. 2C and D; Supplementary Fig. S2B and S2C). Thus, *TFAP2 β* represents a newly identified member of the adrenergic CRC in *MYCN*-amplified NB cells.

Because EP300 binding was enriched at sites containing *GATA3* and *TFAP2 β* motifs, and these proteins bound to H3K27ac-marked chromatin, we sought to determine whether EP300 physically associates with *GATA3* and *TFAP2 β* . Immunoprecipitation of EP300 and CBP in Kelly NB cells, followed by Western blotting for *TFAP2 β* and *GATA3* demonstrated that EP300, but not CBP, physically interacts with both *TFAP2 β* and *GATA3* (Fig. 2G; Supplementary Fig. S2G). In addition, reciprocal co-IP of *TFAP2 β* in Kelly cells demonstrated the presence of EP300 proteins, but not CBP (Supplementary Fig. S2G). To determine whether these TFs are able to control localization of EP300, we performed CRISPR-Cas9-based knockout of *TFAP2 β* or *GATA3* in Kelly NB cells (Fig. 2H; Supplementary Fig. S2H and S2I). As a control, we also performed knockout of *HAND2*, a CRC factor that did not display selective motif enrichment under EP300 peaks (Supplementary Fig. S2J). Day 5 after infection with lentiviruses encoding single-guide RNAs (sgRNA) to knock out *TFAP2 β* , we observed loss of H3K27ac levels without effects on expression levels of EP300 or CBP (Fig. 2H; Supplementary Fig. S2H). In contrast, knockout of either *GATA3* or *HAND2* at the same time points had no or minor effects, respectively, on the levels of H3K27ac (Supplementary Fig. S2I and S2J). Consistent with these findings, genome-wide analysis of *TFAP2 β* binding demonstrated higher correlation with EP300 than CBP in both Kelly and BE2C cells [Spearman ρ for *TFAP2 β* to EP300 0.628 (Kelly), 0.589 (BE2C); to CBP 0.481 (Kelly), 0.492 (BE2C)]. To identify whether knockout of *TFAP2 β* resulted in site-specific or genome-wide loss of H3K27ac, we performed knockout of *TFAP2 β* in Kelly cells using two distinct sgRNAs and then performed CUT&RUN sequencing against H3K27ac




Figure 2. EP300 regulates the NB CRC directed by TFAP2 β . **A**, STRING database interaction plot of nuclear dependency genes in NB cells. Data are derived from ref. 9. Displayed are CRC TFs in blue and proteins with available targeting compounds in red. Connecting lines indicate previously demonstrated protein-protein interactions. **B**, Scatter plot of log₂-transformed read counts of EP300 or CBP ChIP-seq in the collapsed union of separately identified high-confidence CBP- and EP300-binding sites in Kelly cells. *R* indicates the Spearman correlation coefficient demonstrating a strong linear relationship in coverage. See Supplementary Fig. S2A for a similar analysis in BE2C cells. **C**, Genome-wide heat map analysis of chromatin composition at the collapsed union of separately identified high-confidence CRC TF-binding sites in Kelly cells. Rows ordered by EP300 signal. See Supplementary Fig. S2B for a similar analysis in BE2C cells. ATAC-seq, Assay for Transposase-Accessible Chromatin using sequencing. **D**, Representative ChIP-seq plots demonstrating binding of CRC factors (blue), CBP (green), and EP300 (red) at the *PHOX2B* CRC TF locus in Kelly NB cells. Also shown is the *PHOX2B* super-enhancer (H3K27ac) and open chromatin (ATAC-seq, black). Data are representative of both Kelly and BE2C cells and all CRC loci. Values represent normalized reads per million. **E**, Motif enrichment analysis of ChIP-seq to EP300 and CBP in Kelly NB cells. Data were restricted to the top 500 bound peaks by EP300 or CBP in Kelly NB cells. Colored dots indicate known enriched TFs. Arrow indicates specifically enriched motif, corresponding to TFAP2 β . **F**, Position-weight matrix from analysis in **D** demonstrates the top enriched specific sequence under EP300 peaks compared with CBP peaks, corresponding to the consensus binding sequence for TFAP2 β . **G**, Co-IP followed by Western blotting analysis of EP300 and CBP in Kelly NB cells. IgG, isotype-matched rabbit IgG antibody; WCL, whole-cell lysate. Data are representative of three independent co-IP Western blots. **H**, Kelly NB cells expressing Cas9 were infected with sgRNAs targeting TFAP2 β (TFAP2 β -1.2) or control loci (ch2.2, LACZ), followed by Western blotting to the shown targets. Data are representative of three independent lysates and blots. **I**, Genome-wide heat map analysis of H3K27ac coverage in wild-type and TFAP2 β -knockout Kelly cells using cell number and *Escherichia coli* spike-in normalized CUT&RUN sequencing. Rows represent 6-kb regions centered on the center of the collapsed union of high-confidence peaks separately identified in each condition and are ordered by control (ch2.2) signal. **J**, Propidium iodide flow cytometry of Kelly NB cells expressing Cas9 and infected with sgRNAs targeting TFAP2 β (TFAP2 β -1.2) or control loci (ch2.2, LACZ). *n* = 3 independent infections and flow analyses. *, *P* < 0.05. Bars, SEM. See also Supplementary Fig. S2.

with exogenous spike-in *Escherichia coli* DNA controls. Loss of TFAP2 β , but not control loci, resulted in genome-wide loss of H3K27ac (Fig. 2I) without detectable differences between subsets of sites including promoters or nonpromoter regions (Supplementary Fig. S2K). Finally, as with

knockout of EP300, but not with CBP, knockout of TFAP2 β also resulted in G₁ cell-cycle arrest in Kelly and NGP NB cells (Fig. 2J; Supplementary Fig. S2L). In sum, these data indicate that EP300 is targeted to DNA through a physical interaction with the CRC TF TFAP2 β in NB.

EP300 Is Selectively Degraded by a Novel Chemical PROTAC, JQAD1

Each currently available small molecule that inhibits the HAT activity of EP300 also inhibits the HAT activity of CBP with nearly an equivalent K_d (13, 16, 18, 19). This includes A485, the most potent and specific HAT-inhibitory compound toward EP300/CBP developed to date (18, 38). One approach to selectively target EP300 in NB may be to disrupt the interaction between TFAP2 β and EP300; however, a strategy like this has typically been difficult to implement (reviewed in ref. 28). Recently, alternative approaches to develop selective compounds have been described by developing small-molecule degraders, termed “PROTACs.” PROTACs are heterobifunctional small molecules that bind the target protein and mediate the formation of a ternary complex between the target protein and an E3 ligase receptor (reviewed in ref. 27). The ternary complex formed by the PROTAC bridges the target protein to an E3 ubiquitin ligase, which polyubiquitinates the target protein and directs it to the proteasome for degradation and recycling (27). To develop a potential selective compound to target EP300, we used A485 as a bait molecule, because A485 was the most potent small-molecule inhibitor in NB cells and has the lowest K_d value for EP300 and CBP of all small molecules targeting these proteins (ref. 18; Fig. 3A). Computational structural modeling of the interaction between the HAT domain of EP300 and the iMiD-binding region of CRBN indicated that an optimal linker length between A485 and the E3 ligase would be a distance of 8 to 12 atoms. We therefore designed and synthesized an optimized compound containing the two chiral centers found within the A485 molecule (38) and a 12-carbon linking chain, termed JQAD1 (Fig. 3A; Supplementary Data). We synthesized both the (R,S) and (S,S) stereoisomers of this molecule in parallel, and treated three NB cell lines that express high levels of CRBN (Supplementary Fig. S1C) with these compounds. The (R,S) diastereomer had the lowest IC_{50} concentration in intact Kelly, NGP, and SIMA NB cells, and this IC_{50} was lower than that of the parental molecule A485 (Fig. 3B; Supplementary Fig. S3A–S3F). Therefore, the name JQAD1 in this article will refer to the more active (R,S) diastereomer of the PROTAC compound, unless the (S,S) stereoisomer is used as a negative control, as specified.

Next, we sought to determine the interactions of JQAD1 with EP300 and CBP using synthesized biotinylated JQAD1 (Biotin-JQAD1; Supplementary Data) incubated in Kelly cell lysates, followed by streptavidin-based bead purification. Western blotting of Biotin-JQAD1-purified lysates demonstrated the presence of EP300 and CRBN, but surprisingly not CBP proteins (Fig. 3C). This finding indicated that JQAD1 may be selective for EP300 relative to CBP. To further characterize the interaction of JQAD1 with EP300 and CBP, we cotreated Kelly cell lysates with JQAD1 and excess pomalidomide to compete for binding to CRBN, which resulted in a partial loss of the interaction between JQAD1, CRBN, and EP300 (Fig. 3C). These data indicated that these three proteins form a ternary complex. We were excited by the apparent specificity of this PROTAC for binding to EP300, because EP300, but not CBP, is the dominant mediator of H3K27ac in high-risk NB. PROTACs may acquire

preferential specificity for one of two possible target HATs due to restricted three-dimensional interactions (27). In our case, the preferential targeting of EP300 by this PROTAC is an advantage, because NB cells are often exclusively dependent on EP300, while normal cells of different lineages may require CBP, and thus would be spared from toxicity by the specificity of this PROTAC.

Because JQAD1 interacts preferentially with both EP300 and CRBN, we next examined whether JQAD1 preferentially induces degradation of EP300 compared with CBP in *MYCN*-amplified NB cells. Treatment of Kelly cells for 24 hours with JQAD1 demonstrated a dose-dependent decrease in EP300 expression along with a parallel loss of the H3K27ac modification (Fig. 3D). Similar treatment of Kelly cells with A485 caused a loss of H3K27ac due to catalytic inhibition of EP300 enzymatic activity (Fig. 3D). Treatment of Kelly cells with (R,S)-JQAD1 and the control (S,S)-JQAD1 for 24 hours revealed that (S,S)-JQAD1 had limited effects on H3K27ac or EP300 expression levels, while (R,S)-JQAD1 suppressed both H3K27ac and EP300 expression levels (Supplementary Fig. S3G). Consistent with the specificity of JQAD1 for EP300, we noted that neither compound had significant effects on CBP expression levels at this time point (Supplementary Fig. S3G). To comprehensively characterize the specificity of JQAD1 for EP300 at this time point, we performed an analysis of the effects of JQAD1 by stable isotope labeling of amino acids in cell culture (SILAC; Fig. 3E). Kelly cells were cultured with SILAC media containing heavy- or light-labeled arginine and lysine. Heavy-labeled cells were treated with 500 nmol/L JQAD1, and light-labeled cells treated with DMSO for 24 hours, prior to nuclear extraction and protein lysis. As a control, we performed nuclear extraction and lysis on untreated heavy- and light-labeled Kelly cells. Protein abundance was then analyzed by mass spectrometry to determine global changes in the nuclear proteome. After 24 hours of treatment with JQAD1, EP300 protein was significantly decreased ($P = 3.3 \times 10^{-5}$), while CBP and other proteins within the nuclear proteome remained detectable at similar levels as controls (Fig. 3E). Next, we treated three NB cell lines, Kelly, NGP, and SIMA, that have high protein expression levels of CRBN (Supplementary Fig. S1C) with JQAD1 and then measured the effects on specific proteins by Western blotting. In all three cell lines, JQAD1 induced selective loss of EP300 expression coincident with cleavage of PARP1, signaling the onset of apoptosis (Fig. 3F; Supplementary Fig. S3H). At this time point in all three cell lines, CBP could still be detected. With extended treatment, we also noted loss of CBP expression, although markers of apoptosis (cleaved PARP1) could be detected prior to the loss of CBP protein expression (Fig. 3F; Supplementary Fig. S3H).

JQAD1 contains an iMiD moiety that interacts with the E3 ligase receptor CRBN (Fig. 3A and C). To further demonstrate this interaction, we used the AlphaLISA platform (39) to perform AlphaLISA fluorescent assays using bead-bound biotinylated pomalidomide and His-tagged CRBN. Multiple iMiD-containing compounds, including JQAD1 and free pomalidomide, efficiently interacted with CRBN by the AlphaLISA assay, while the parental compound A485 did not (Supplementary Fig. S3I). We next sought to establish whether CRBN proteins are required for JQAD1-mediated




Figure 3. JQAD1 is a selective EP300 degrader. **A**, Chemical structure of (R,S)-A485 and (R,S)-JQAD1. **B**, Kelly cells were treated with 1 $\mu\text{mol/L}$ (R,S)-A485, (R,S)-JQAD1, (S,S)-JQAD1, or DMSO for 6 days, and growth was measured by CellTiter-Glo assay. $n = 3$ independent experiments and measurements at each time point. Bars, SEM. **C**, Kelly cell lysates were treated with combinations of Biotin-JQAD1 or pomalidomide prior to streptavidin-bead purification and Western blotting of protein isolates demonstrating enriched interaction of JQAD1 with CRBN and EP300 proteins. WCL, whole-cell lysate. Data are representative of three independent experiments and blots. **D**, Kelly NB cells were treated with DMSO, A485, or JQAD1 at the noted concentrations (in $\mu\text{mol/L}$) for 24 hours prior to lysis for Western blotting. Data are representative of three independent biological repeats. **E**, SILAC-labeled Kelly NB cells were treated with JQAD1 at 500 nmol/L or DMSO vehicle for 24 hours prior to nuclear extraction and analysis by mass spectrometry. Ratio of detected peptides at 0 hours versus 24 hours is demonstrated. Data represent the sum ratio of heavy:light-labeled protein detected in triplicate at 24 hours compared with 0 hours. Dotted line indicates a P value of 0.01. Red labeled points indicate EP300 and CBP. $n = 3$ independent treatments, lysates, and mass spectrometry reactions. **F**, Kelly NB cells were treated with JQAD1 at 500 nmol/L for the noted time points prior to lysis for Western blotting. Data are representative of three independent experiments and blots. Asterisk (*) indicates cleaved PARP1 species. **G**, Kelly cells stably expressing Cas9 were infected with sgRNAs targeting *CRBN* (CRBN-1,3) or control loci (ch2.2, LACZ), and pools of knockout (KO) cells were established. Western blotting was performed with antibodies against CRBN. Actin is shown as a loading control. Data are representative of three independent Western blots. **H**, Kelly Cas9 control or *CRBN*-knockout cells were treated with a range of doses of JQAD1 for seven days, prior to assay by CellTiter-Glo. $n = 3$ independent replicates per dose and time point. **I** and **J**, Propidium iodide flow cytometry of sub- G_1 events in Kelly (**I**) and NGP (**J**) cells treated with JQAD1 or A485 for the noted time points (in hours). Data are a summary of $n > 3$ independent flow experiments. Compound treatment was performed at 500 nmol/L (Kelly) and 1 $\mu\text{mol/L}$ (NGP). Similar results were obtained in SIMA cells treated with compounds at 1 $\mu\text{mol/L}$. Bars, SEM. See also Supplementary Fig. S3.

EP300 degradation and cellular effects. To do so, we used CRISPR-Cas9 gene editing to produce Kelly cells with stable disruption of the *CRBN* gene. Western blotting of lysates prepared from control or *CRBN*-edited Kelly cells demonstrated loss of CRBN expression in *CRBN*-edited cells, with

retained expression in control-edited cells (Fig. 3G). Control-edited Kelly cells were potently killed by JQAD1; however, *CRBN*-knockout cells were resistant to the effects of JQAD1, indicating that CRBN expression was required for JQAD1 growth-suppressive activity (Fig. 3H). In contrast, A485

equivalently inhibited the growth of both *CRBN*-knockout cells and controls (Supplementary Fig. S3J), indicating that loss of *CRBN* has no effect on the enzymatic function of EP300. Western blotting of lysates prepared from control and *CRBN*-knockout Kelly cells treated with JQAD1 or DMSO demonstrated that JQAD1 suppressed EP300 expression, suppressed the H3K27ac modification, and induced apoptosis, marked by PARP1 cleavage in control cells, but not in *CRBN*-edited cells (Supplementary Fig. S3K). Thus, *CRBN* is required for JQAD1-mediated EP300 degradation and induction of apoptosis. Because treatment of *CRBN*-edited cells with JQAD1 had no effect on H3K27ac, we hypothesize that the structure of JQAD1 prevents its A485 moiety from competitively inhibiting EP300 HAT activity, and therefore it acts as a *CRBN*-dependent protein degrader, without significant catalytic inhibitory activity (Supplementary Fig. S3K). To further probe the pathway involved in JQAD1-mediated EP300 degradation, we next performed Western blotting on Kelly cells cotreated with JQAD1 and other compounds predicted to disrupt JQAD1 function. Degradation of EP300 was blocked by cotreatment with excess A485, an IMiD (pomalidomide), and E3 ubiquitin ligases neddylation (MLN4924), and more minimally by inhibition of the proteasome (bortezomib; Supplementary Fig. S3L). These data indicate that JQAD1 functions by binding to EP300, which leads to *CRBN*-dependent proteasomal degradation of EP300 and cell death.

JQAD1 Causes Apoptosis Concurrent with MYCN Downregulation

Next, we sought to evaluate the mechanism by which JQAD1 reduced cell growth. We treated Kelly and NGP cells with JQAD1, A485, or vehicle control and performed propidium iodide (PI) DNA flow cytometry. Cells treated with A485 to inhibit EP300/CBP catalytic activity underwent G₁ cell-cycle arrest (Supplementary Fig. S3M). Strikingly, (R,S)-JQAD1 treatment resulted in early time-dependent induction of a sub-G₁ peak, suggestive of apoptotic cell death (Fig. 3I and J; Supplementary Fig. S3N). To more deeply characterize the differences between HAT inhibition and EP300-selective degradation on NB apoptosis, we treated Kelly and NGP cells for 12 to 36 hours with equal concentrations of either A485 or JQAD1 prior to extracting protein to analyze effects on apoptosis. Treatment of both cell lines with JQAD1 resulted in cellular apoptosis, marked by cleavage of caspase 3 and PARP1. In contrast, A485 treatment had little effect on these parameters at these time points (Fig. 4A; Supplementary Fig. S4A). To identify the mechanism underlying this difference in response between degradation of EP300 and catalytic inhibition of both EP300 and CBP, we next treated Kelly NB cells with equivalent concentrations of DMSO, JQAD1, or A485 for 24 hours and performed RNA-sequencing (RNA-seq) analysis with exogenous spike-in RNA normalization. RNA-seq results for JQAD1- and A485-treated samples were then compared by gene set enrichment analysis (GSEA). Consistent with our DNA flow cytometry studies, analysis of GSEA results with the Molecular Signatures Database (MSigDB) hallmark gene sets demonstrated enrichment of the “apoptosis” gene set in JQAD1-treated cells compared with A485-treated cells (Fig. 4B). Furthermore, JQAD1-treated cells exhibited upregulation of the proapoptotic BH3-only effectors BIM, BID, and

PUMA together with the proapoptotic mediator BAX and its inhibitors BCL2 and MCL1, while transcript levels for each of these mRNAs was unaffected in A485-treated cells at this time point (Fig. 4C). The induction of apoptotic cell death at an early time point with JQAD1, compared with A485 treatment, suggests that there may be a HAT-independent activity contributing to the apoptosis observed with EP300 degradation.

One mechanism by which NB cells repress apoptosis is through high-level expression and transcriptional activity of the MYCN oncoprotein, sometimes referred to as “oncogene addiction” (reviewed in refs. 40, 41). EP300 and CBP regulate the MYCN family member c-MYC protein through protein-protein interactions (42–44), so we hypothesized that a similar physical interaction between MYCN and EP300 might exist, resulting in MYCN localization at chromatin. To examine this hypothesis, we performed co-IP assays with antibodies targeting either endogenous EP300 or CBP in Kelly NB cells. Immunoprecipitation of protein from Kelly nuclear lysates with anti-EP300 antibodies followed by Western blotting demonstrated pronounced association with MYCN protein. In contrast, immunoprecipitation of CBP, like IgG controls, did not reveal detectable MYCN protein (Fig. 4D). Thus, in Kelly NB cells, EP300, but not CBP, physically interacts with the MYCN oncoprotein.

To evaluate the functional significance of this interaction, we next treated Kelly NB cells with DMSO or two concentrations of either A485 or JQAD1 for 24 hours and isolated proteins associated with chromatin (Fig. 4E) or whole-cell lysate (Fig. 4F). Kelly cells treated with A485 demonstrated stable levels of MYCN proteins in chromatin extracts and whole-cell lysates up to 1.0 μmol/L (Fig. 4E and F). In contrast, cells treated with JQAD1 to degrade EP300 showed loss of both EP300 and MYCN proteins from the chromatin-associated protein fraction and whole-cell lysate (Fig. 4E and F). To examine whether MYCN is the primary mediator of EP300 function, we overexpressed in Kelly cells either MYCN cDNA or EGFP control cDNA tagged with a nuclear localization sequence using lentiviral infection. Western blotting demonstrated that MYCN-overexpressing cells had higher detectable levels of MYCN, and these two infected pools expressed equivalent amounts of EP300 and CBP (Supplementary Fig. S4B). We then examined the response of these cells to JQAD1 in CellTiter-Glo growth assays and found that slightly higher dosages of JQAD1 are required to cause reduced growth in NB cells overexpressing MYCN, after treatment with JQAD1. The IC₅₀ of the MYCN-overexpressing cells was shifted slightly to 121 nmol/L from 95 nmol/L in EGFP-overexpressing cells (Supplementary Fig. S4C). MYCN-overexpressing Kelly cells were somewhat less responsive to JQAD1 treatment by CellTiter-Glo analysis, indicating that MYCN reexpression is insufficient to correct for the loss of EP300. These data suggest that one effect of EP300 degradation is rapid loss of MYCN expression, whereas inhibition of EP300 HAT activity requires much more prolonged treatment to induce the same levels of MYCN repression (Supplementary Fig. S1N).

JQAD1 Causes Loss of H3K27ac at Chromatin

Because JQAD1 selectively degrades EP300 with minimal effects on CBP until 48 hours in NB cell lines, we next used this compound to identify the effects of EP300 loss on




Figure 4. EP300 degradation rapidly disrupts MYCN expression and causes apoptosis. **A**, Kelly NB cells were treated with 1 $\mu\text{mol/L}$ JQAD1, A485, or DMSO control for 12, 24, or 36 hours, prior to lysis and Western blotting for the markers of apoptosis: cleaved caspase-3 and cleaved PARP1. Actin is demonstrated as a loading control. Data is representative of three independent treatments and analyses in Kelly and NGP cells. **B**, Kelly cells were treated with 500 nmol/L JQAD1, A485, or DMSO control for 24 hours prior to External RNA Controls Consortium (ERCC)-controlled spike in RNA-seq. GSEA of RNA-seq results was performed with the MSigDB hallmarks dataset. $n = 3$ biological replicates and independent RNA extractions per treatment. **C**, Normalized RNA-seq gene expression of pro- and antiapoptotic mRNA transcripts from Kelly cells treated as in **B**. Log₁₀ transcript expression is shown, normalized against DMSO and ERCC controls. $n = 3$ biological replicates and independent RNA extractions per treatment. Bars, SEM. **D**, Nuclear lysates from Kelly cells were immunoprecipitated with anti-EP300, anti-CBP, or IgG control antibodies. WCL, whole-cell lysates. Data is representative of >3 independent co-IP/Western blots. **E** and **F**, Kelly cells were treated with DMSO control, A485 (0.5, 1 $\mu\text{mol/L}$), or JQAD1 (0.5, 1 $\mu\text{mol/L}$), followed by extraction of chromatin (**E**) or whole-cell lysates (**F**) and Western blotting. Total H3 is shown as a loading control. Data are representative of three independent biological replicates. See also Supplementary Fig. S4. NES, normalized enrichment score.

genome-wide H3K27ac. We performed ChIP-seq with antibodies recognizing H3K27ac in Kelly NB cells, over a time course from 0 to 24 hours after exposure to (R,S)-JQAD1. These samples were externally normalized using spike-in *Drosophila melanogaster* chromatin. Comparison of H3K27ac-marked sites to untreated samples demonstrated approximately twofold general suppression genome-wide by 24 hours of treatment at a time when EP300 was degraded and CBP was retained (Fig. 5A). While comparison of H3K27ac signal at earlier time points (6 hours) to 0-hour controls demonstrated no consistent changes in acetylation, by 24 hours of treatment, there was general loss of H3K27ac signal genome-wide, which was most pronounced at densely acetylated super-enhancers, including those regulating the CRC (Fig. 5B-D; Supplementary Fig. S4D). These data indicate that super-enhancer loci in Kelly cells are regulated predominantly by EP300 and not CBP, because at this time point, EP300 is degraded without effects on the levels of CBP protein expression (Fig. 5D; Supplementary Fig. S4D).

JQAD1 Is Effective with Limited Toxicity *In Vivo*

Some CRBN-based PROTAC agents cause target protein degradation *in vivo* (reviewed in ref. 27). Thus, we next sought to identify whether JQAD1 would degrade EP300 *in vivo* in human NB xenografts. First, we performed pharmacokinetic analysis after a single intraperitoneal (i.p.) dose of JQAD1

at 10 mg/kg, to identify the half-life and maximum serum concentration of the compound. We found that after 10 mg/kg i.p. dosage, JQAD1 has a half-life of 13.3 (± 3.37 SD) hours in murine serum, with a C_{max} of 7 $\mu\text{mol/L}$ (Supplementary Fig. S5A), which is well above the IC_{50} of human NB cells *in vitro* (Supplementary Fig. S3A-S3C). Then we sought to identify the MTD in murine models. To do so, we performed daily intraperitoneal injection of JQAD1 at increasing doses in CD1 mice. Daily treatment with JQAD1 was well tolerated with no signs of animal weight loss (Supplementary Fig. S5B). At doses of JQAD1 higher than 40 mg/kg, we experienced problems with the compound forming precipitates in the peritoneal cavity. Thus, 40 mg/kg of JQAD1 was determined to be the maximal dosage we could administer intraperitoneally without evident toxicity in the mouse.

Next, we established subcutaneous xenografts of Kelly cells in the flanks of NSG mice and treated mice with either vehicle control or JQAD1 at 40 mg/kg i.p. once daily (Fig. 6A). JQAD1 treatment suppressed xenograft tumor growth by day 3 of treatment ($P < 0.0001$ for suppressed growth rates in JQAD1-treated tumors by mixed-effects analysis with *post hoc* Tukey multiple comparisons test), and prolonged tumor-bearing animal survival compared with vehicle controls (log-rank test $P = 0.0003$ for JQAD1-treated tumors compared with vehicle control; Fig. 6A and B). We also monitored for effects of JQAD1 treatment on animal weight. Body weight




Figure 5. JQAD1 causes genome-wide loss of histone H3K27ac enriched at super-enhancers. **A**, Enhancers were ranked by H3K27ac signal at 0 hours (left) and 24 hours (right) after treatment of Kelly cells with 500 nmol/L JQAD1. Data are representative of two independent treatments and ChIP-seq experiments. **B**, Log₂ fold change in enhancer H3K27ac signal resolved by H3K27ac ChIP-seq in Kelly NB cells at 0 versus 6 hours (left) and 0 versus 24 hours (right). **C**, Log₂ fold change in enhancer H3K27ac signal stratified by super-enhancers and typical enhancers at 6 and 24 hours after treatment of Kelly cells with 500 nmol/L JQAD1. ***, $P < 0.0001$ by Student *t* test comparing super-enhancer- and typical enhancer-regulated genes at 24 hours. Bars, SEM. **D**, Representative gene tracks of Kelly cells treated with JQAD1 at 500 nmol/L for 0 and 24 hours at the *HAND2* CRC factor loci (*HAND2*, *ISL1*, *PHOX2B*, *GATA3*, *TBX2*, *ASCL1*, and *TFAP2B*) and two independent treatments and ChIP-seq experiments. See also Supplementary Fig. S4.

was maintained over 15 days of treatment, prior to when control animals began to display rapidly enlarging tumors (Fig. 6C). Separately, NSG mice were xenografted with Kelly cells and treated with vehicle control or JQAD1 daily at 40 mg/kg for 10 days. Animals were then sacrificed, and the tumors were extracted. Tumor material was fixed for IHC and processed for External RNA Controls Consortium (ERCC)-controlled RNA-seq analysis (Fig. 6D and E). Tumors recovered from animals treated with JQAD1 displayed a loss of EP300, but retained CBP immunostaining, compared with vehicle control tumors (Fig. 6D). Consistent with our *in vitro* studies, RNA expression profiles of tumor cells from mice treated with JQAD1, compared with vehicle control demonstrated preferential downregulation of genes regulated by super-enhancers compared with those regulated by typical enhancers (Fig. 6E, $P < 0.0001$).

Human CRBN differs from mouse at a key residue, CRBN^{Val388} compared with Crbn^{Ile391} in the mouse, which is important for binding, ubiquitinating, and degrading key substrates (45, 46). To more rigorously assess the potential activity and toxicities of JQAD1 on murine tissues, we administered JQAD1 at 40 mg/kg *i.p.* daily for 21 days to Balb/c *Crbn*^{Ile391Val}-humanized knock-in mice (46). JQAD1 at this dosage was well tolerated, with no effects on grooming, behavior, weight, peripheral blood counts, liver function tests, or creatinine measurements performed after 14 days of treatment (Supplementary Table S2; Supplementary Fig. S5C). After 14 days of treatment, three mice per each treatment group were sacrificed and skin, brain, heart, lung, liver, spleen, kidney, pancreas, small intestine, colon, adrenal gland, and bladder were extracted and processed for pathologic analysis. Tissues were evaluated by an independently blinded




Figure 6. JQAD1 causes tumor growth suppression and loss of EP300 *in vivo*. **A**, Kelly NB cell xenografts were established in NSG mice and mice treated with vehicle control ($n = 9$) or JQAD1 at 40 mg/kg i.p. daily ($n = 10$). Tumor growth curve kinetics were also analyzed by two-way ANOVA with mixed-effects analysis, demonstrating that JQAD1 suppresses tumor growth ($P < 0.0001$ for vehicle vs. JQAD1 treatment groups). **B**, Kaplan-Meier survival analysis of mice in **A**. JQAD1 prolongs survival (log-rank test $P = 0.0003$ for JQAD1-treated mice compared with vehicle). **C**, Normalized body weights of animals from **A** and **B**. **D**, IHC of EP300 and CBP in Kelly cell xenografts treated with either vehicle control or JQAD1 (40 mg/kg i.p. daily) for 14 days. Data are representative of three independent animals per treatment. Scale bar, 50 μm . **E**, ERCC spike-in RNA-seq was performed on tumor cells recovered from animals treated in **D**. Results are shown as the fold change in expression of animals treated with 40 mg/kg JQAD1 daily ($n = 3$) compared with vehicle control ($n = 4$) at day 14. RNA-seq groups of genes are stratified by their regulation by typical or super-enhancers and gene identity of TF or CRC gene. ***, $P < 0.0001$ between typical enhancer and super-enhancer groups and between typical enhancer and CRC gene expression; *, $P = 0.0223$ between super-enhancer groups and CRC gene expression; **, $P = 0.0013$ between all TFs and CRC gene expression. See also Supplementary Fig. S5.

pathologist with hematoxylin and eosin staining for evidence of toxicity. This revealed no gross changes in tissue architecture or immune infiltrate, consistent with a lack of toxicity. To establish whether JQAD1 was selective in degrading EP300 and not CBP *in vivo*, we then performed IHC against EP300 and CBP on liver tissues from Balb/c *Crbn*^{ILE391VAL} mice treated with vehicle control or JQAD1. This analysis demonstrated that JQAD1-treated animals had reduced EP300, but not CBP protein expression levels, in liver cell nuclei compared with vehicle-treated controls (Supplementary Fig. S5D). Consistent with the hypothesis that CBP could partially compensate for loss of EP300, JQAD1-treated animals displayed no histologic or biochemical evidence of toxicity in the liver.

Previously, we identified that MYCN and each of the master TF members of the adrenergic CRC are dependencies in NB (9). Because EP300 dominantly catalyzes the H3K27ac mark, we hypothesized that EP300 might preferentially be responsible for the high levels of expression of CRC master TFs. Further, because JQAD1 preferentially degrades EP300, the HAT that primarily catalyzes H3K27ac seen at super-enhancers and those of the CRC in particular, we reasoned

that treatment with JQAD1 might have major effects on the expression levels of genes in the CRC. Therefore, we compared the effects of JQAD1 given daily for 14 days on the expression levels of several different classes of mRNAs, including those regulated by typical enhancers, super-enhancers, and all TFs as well as TFs that encoded known CRC members (Fig. 6E; Supplementary Fig. S5E). This revealed that the CRC genes, along with MYCN, were among the most downregulated genes in tumors treated with JQAD1, compared with genes in the other categories. GSEA of the MSigDB cancer hallmarks dataset revealed five of 50 cancer hallmarks downregulated in JQAD1-treated tumor samples, with an FDR < 0.25 and NOM $P < 0.05$ (Supplementary Fig. S5F). Consistent with our finding that MYCN was among the most downregulated genes in tumors treated with JQAD1 *in vivo*, these hallmark gene sets included an enrichment for MYC target genes (Supplementary Fig. S5G and S5H). These results demonstrate that JQAD1 treatment *in vivo* strongly downregulates the expression of the very important subset of genes that encode TFs comprising the CRC, including MYCN, which are NB growth dependencies (9, 35).




Figure 7. Cancer cells display increased dependency on EP300 compared with CBP. **A**, Probability of dependency of all cell lines in DepMap ($n = 757$, 20Q2 release), on EP300 and CBP were compared, demonstrating dependency on EP300 in 308 of 757 (40.7%) and CBP in 140 of 757 (18.5%) of all cell lines, determined by probability of dependency > 0.5 . ***, $P < 0.0001$ by two-tailed Student t test. AML, acute myeloid leukemia; CML, chronic myeloid leukemia; NOS, not otherwise specified. **B**, Individual lineages of cell lines from **A** were identified, and average probability of dependency on EP300 and CBP were plotted. Red, NB; black, other tumor lineages; bar in box, median; whiskers, 10th–90th centiles; dots, outliers. **C**, Barcoded cancer cell lines ($n = 557$) were treated with a concentration range of (R,S)-JQAD1 of 1.2 nmol/L to 20 μ mol/L for 5 days prior to sequencing of barcodes. Cell lines were individually classified by lineages, and AUC of the dose–response relationship was plotted. Red bars, median; individual black dots, individual cell lines; red dots, NB cell lines. AUC was calculated from triplicate measurements at each dose at time = 120 hours. (continued on following page)

JQAD1 Has Broad CRBN-Dependent Antineoplastic Activity across Cancer Cell Lines

Epigenetic- and enhancer-mediated control of gene expression is required for normal cellular and tissue developmental processes and is dysregulated in different cancer subtypes (reviewed in refs. 2, 28). We therefore hypothesized that in addition to NB, there may be a preferential reliance on EP300 or CBP in other cancer types. Thus, we examined the relative

dependence of all available cell lines on EP300 or CBP using the DepMap genome-scale CRISPR–Cas9 loss-of-function screening dataset (30). Comparison of the probability of dependency on EP300 and CBP across a total of 757 human cancer cell lines, representing 36 distinct tumor lineages, demonstrated a higher probability of dependency on EP300 than CBP across many cancer cell lines ($P < 0.0001$, Fig. 7A). We also stratified all cell lines in DepMap by tumor lineage and




Figure 7. (Continued) D–F, NB and control cell lines were grown for 6 days in the presence of JQAD1 in a dose range from 4.3 nmol/L to 20 μ mol/L prior to CellTiter-Glo analysis. Dose–response curves are based on three independent replicates per cell line at each dose. Bars, SEM. Analysis was performed on MYCN-amplified (D), nonamplified (E), and control (F) cell lines, including 293T cells and primary human fibroblasts (CCLF_PEDS_0046_N). All cell lines are of the adrenergic subtype except for NB5 and SKNMM (unknown), and CHP212, SHEP, and SKNAS (mesenchymal). Adrenergic or mesenchymal cell state annotations are derived from refs. 33 and 69. G, JQAD1 AUC values from C were plotted against CRBN expression from the CCLE. ***, $P < 0.001$ by ANOVA for >5 transcripts per million (TPM) compared against <4 and 4 to 5 TPM groups with *post hoc* Bonferroni correction. H, BE2C cells stably expressing control (zsGreen) or CRBN (CRBN) were established, and pools of cells were treated with DMSO or 10 μ mol/L JQAD1 for 24 hours. Cell lysates were subjected to Western blotting for EP300, CBP, and CRBN. Actin is shown as a loading control. Data are representative of three independent treatments and analyses. I, BE2C cells stably expressing control (zsGreen) or CRBN (CRBN) were treated with DMSO or 10 μ mol/L JQAD1 for 6 days prior to CellTiter-Glo analysis for cell growth. Data were normalized against BE2C-zsGreen, DMSO-treated cells. ***, $P = 0.008$ by Student *t* test comparing BE2C-CRBN DMSO- and JQAD1-treated cells. $n = 3$ biological replicates. See Supplementary Fig. S6.

examined the probability of dependency on EP300 and CBP in each lineage. By this analysis, many tumor lineages displayed an enhanced probability of dependency on EP300 compared with CBP (Fig. 7B). Few tumor cell lineages, notably thyroid, pancreatic, and cervical carcinomas, displayed enhanced dependency on CBP compared with EP300 (Fig. 7B).

Because the probability of dependency on EP300 was higher for many tumor lineages than that of CBP, we next sought to determine whether JQAD1 would display anti-neoplastic effects across multiple tumor lineages. To do so, we analyzed the response to JQAD1 in a pooled, barcoded 5-day cell viability PRISM screen of 557 cancer cell lines

(Fig. 7C; ref. 47). These results demonstrated that JQAD1 treatment had antineoplastic activity across multiple tumor lineages, many of which displayed enhanced dependency on EP300 compared with CBP. Within most tumor lineages, there were cell lines that displayed growth inhibition with JQAD1 treatment (area under the curve, AUC < 0.85; Fig. 7C). Validation of these results in a wide array of NB cell lines by CellTiter-Glo analysis demonstrated that many were sensitive to JQAD1, including *MYCN*-amplified and *MYCN* nonamplified cell lines (Fig. 7D and E). Further, two control cell lines, 293T and primary human fibroblasts, were unaffected by JQAD1 to a maximum dose of 20 $\mu\text{mol/L}$, suggesting that the low *in vivo* toxicity we identified may reflect lower toxicity in nontumorigenic cells (Fig. 7F). Further study will be required to determine whether the specificity of JQAD1 will translate to lower toxicity and a broader therapeutic index for cancers selectively dependent on EP300 compared with CBP.

Because cell lines from multiple lineages displayed growth suppression with JQAD1 treatment, we next sought to identify whether predictors of JQAD1 activity could be determined. To do so, we performed an analysis of RNA expression profiles of all cell lines treated with JQAD1. Consistent with its mechanism of action, we noted that higher expression levels of *CRBN* were correlated with higher JQAD1-mediated antineoplastic activity, as reflected by a lower AUC measurement of JQAD1 dose response (Fig. 7G). This indicated that JQAD1 activity is at least partially determined by *CRBN* expression levels, which is consistent with the requirement by JQAD1 for *CRBN* to target EP300 for degradation. To further investigate this requirement, we hypothesized that increasing the expression levels of *CRBN* in JQAD1-resistant NB cells may result in restoration of sensitivity. Thus, we examined BE2C NB cells, which have lower *CRBN* protein expression and are less sensitive to JQAD1 than many other NB cell lines (Supplementary Fig. S1C; Fig. 7D). We established BE2C cells with stable overexpression of *CRBN* (BE2C-*CRBN*) or, as a control, zsGreen (BE2C-zsGreen) and treated these cells with JQAD1 or vehicle control (Fig. 7H). EP300 was degraded within 24 hours of treatment with JQAD1 in BE2C-*CRBN* cells, while expression of EP300 in control cells was unaffected (Fig. 7H). Further, the growth of BE2C-*CRBN* cells was suppressed by JQAD1 treatment, while untreated BE2C-*CRBN* cells grew at similar rates as BE2C-zsGreen cells treated with DMSO or JQAD1 (Fig. 7I). Thus, *CRBN* overexpression in JQAD1-insensitive BE2C cells is sufficient to restore sensitivity to JQAD1. Finally, to understand whether *CRBN* expression was variable in primary NB tumors, we examined the intertumoral expression of *CRBN* in two large NB cohorts using the R2 database. This demonstrated that *CRBN* has similar mean expression values with overlapping 95% confidence intervals across patient groups divided according to prognostic variables such as patient age (Supplementary Fig. S6A and S6F), tumor stage (Supplementary Fig. S6B and S6G), or *MYCN* amplification status (Supplementary Fig. S6C and S6H). Further, there was no apparent correlation between expression levels of *CRBN* and levels of either *MYCN* (Supplementary Fig. S6D and S6I) or *c-MYC* (Supplementary Fig. S6E and S6J). Then, to assess for potential intratumoral heterogeneity of *CRBN* expression in patient tumor samples, we reanalyzed a recently published, publicly available dataset of single-cell RNA-seq from

16 primary NB tumors. Here, *CRBN* expression was found diffusely throughout the entire malignant cell population, without clear subsets of tumor cells with differential expression (Supplementary Fig. S6K). Thus, there does not appear to be significant heterogeneity in *CRBN* expression across or within primary NB tumors. These data underscore that two important considerations for using degraders across distinct cell models are (i) individual cell line dependency on the PROTAC target and (ii) expression levels of key components of the PROTAC machinery, such as *CRBN*. In summary, these data indicate that cancer cells beyond NB display enhanced dependency on EP300 compared with CBP and that JQAD1 represents a potential method to capitalize on this enhanced dependency, especially in individual tumors with elevated *CRBN* expression levels.

DISCUSSION

EP300 and CBP are paralogous, multidomain protein acetyltransferases with broad cellular functions mediated by protein-protein interactions and catalytic acetyltransferase activities (13). These proteins are independently mutated or translocated in a variety of human cancers, and studies have identified distinct but overlapping activities of these proteins in untransformed cell types, including embryonic and hematopoietic stem cells and more differentiated fibroblasts and T cells (20, 21, 48–50). EP300 and CBP display largely overlapping but partially distinct binding patterns across the genome, indicating that these proteins exhibit only partial functional redundancy in transcriptional regulation (24, 25). Due to their high degree of homology, especially in the HAT and bromodomains, it has been difficult to study their function independently and design small-molecule inhibitors that are selective for either. To this end, studies have demonstrated that EP300 exhibits synthetic lethality in cell lines in which CBP is mutationally inactivated (23). However, both enzymes are expressed in most cell lines and primary tissues, making it difficult to distinguish between their individual functions.

Here, we demonstrate that most childhood NBs display selective dependency on EP300 and not on CBP. By studying this dependency on EP300, we identified that the TF TFAP2 β is a key member of the CRC that cobinds genome-wide with the known CRC factors. CRCs are lineage-defining autoregulatory TF networks that establish the transcriptional landscapes of different types of cells (9, 35, 51–53). EP300 and CBP do not bind DNA in a sequence-specific manner and so depend on TFs to localize them to their target loci. Importantly, the TF TFAP2 β specifically binds EP300, but not CBP, and is responsible for recruiting EP300 to its targets in NB cells. Loss of TFAP2 β , but not the CRC TFs HAND2 or GATA3, results in loss of the H3K27ac mark on CRC-associated super-enhancers catalyzed by EP300 in NB cells, thereby identifying TFAP2 β as a primary mediator of EP300 localization to critical super-enhancers. This mechanism results in direct EP300 regulation of lineage-specifying and oncogenic loci in NB by CRC-dependent recruitment. This function cannot be accomplished by CBP, because it does not physically interact with TFAP2 β . In addition to TFs, CRCs include enhancer RNAs and linker proteins such as LDB1 and LMO1 that are integral components of this regulatory complex (35,

51, 54). With evidence that coactivator proteins are found at genomic loci bound by CRC TFs (55) and that loss of EP300 results in enhanced loss of CRC factor expression compared with other TFs *in vivo*, we posit that coactivator enzymes such as EP300 are critical for the high levels of expression that define genes of the CRC extended regulatory network. Moreover, lineage- and tumor-specific CRC factors, such as TFAP2 β in NB, play a role in the CRC complex by recruiting EP300 to establish the malignant cell state.

There is a striking enrichment for dependency on EP300, compared with CBP in various cancer subtypes, consistent with the hypothesis that these two paralogous genes may play context-dependent, distinct roles in regulating cancer cell survival. As a result, selective targeting of EP300 in different types of cancer cell lines that are dependent of EP300 may be effective for eliciting antitumor activity with reduced toxicity because CBP is still active in normal cells and may be able in most normal cells to compensate for the loss of EP300. This attractive hypothesis has been hard to test because of significant homology between these two proteins, which has prevented pharmacologic strategies to preferentially target one of these enzymes while sparing the other.

Here, we generated a novel PROTAC, termed JQAD1, which relies on the nonselective EP300- and CBP-binding compound A485 as a binding molecule but is selective in its ability to degrade EP300 compared with CBP. This selectivity stands in marked contrast to the more promiscuous acetyltransferase inhibitory activity of A485 against both EP300 and CBP. PROTAC agents synthesized from bait molecules with binding to several closely related proteins can display substrate specificity, such as with BRD4 and p38 degraders (reviewed in ref. 27). Recently, a degrader molecule has been reported that degrades both EP300 and CBP indiscriminately, using a bait molecule that targets the bromodomain of these proteins (56). We therefore hypothesize that the mechanism of JQAD1 selectivity is likely to be related to three-dimensional interactions between the targeted protein and the E3 ligase complex, mediated by the different binding component of the PROTAC. Due to the size of full-length EP300 and CBP proteins, full-length crystal structures have not been resolved, and as a result, this hypothesis remains unproven. However, we note that Biotin-JQAD1 forms a ternary complex with EP300 and CRBN, which does not contain CBP. Thus, in contrast to A485, which has equivalent binding activity to EP300 and CBP, JQAD1 binds more avidly to EP300 than CBP in the presence of CRBN. Our data indicate that JQAD1 strongly and preferentially degrades EP300. With continuous prolonged treatment *in vitro*, however, we observed loss of CBP. This is not observed *in vivo*, where more complex mechanisms of compound processing, bioavailability, and excretion are at play. The effects of JQAD1 on CBP *in vitro* may be related to concurrent apoptotic processes such as activation of nuclear proteases, or CBP may serve as a secondary target after depletion of EP300. Further exploration of the mechanism of kinetic selectivity of PROTACs and indeed cocrystallization of full-length CRBN with JQAD1 bridging to EP300 will be required to thoroughly resolve the basis for preferential degradation of EP300 by JQAD1.

JQAD1 has several intriguing properties: (i) It demonstrates preference for EP300 relative to CBP in multiple NB cell lines; (ii) it has higher potency than the parental inhibitor

in some cell lines; (iii) it induces EP300 degradation in a time-dependent manner as early as 16 hours, which contrasts with other methods of selective disruption of EP300, such as knockdown or knockouts; and (iv) it is useful for degradation of EP300 with limited effects on CBP and limited toxicities *in vivo*. EP300 is degraded by JQAD1 *in vivo* in normal murine tissues that express humanized CRBN; however, CBP immunostaining is only minimally affected in these tissues. Furthermore, these tissues display normal architecture. These findings support the hypothesis that CBP may compensate for the loss of EP300 in some normal tissues. Accordingly, we were not able to identify toxicities in mice treated twice daily with 40 mg/kg JQAD1 i.p. for 14 days after profiling blood counts, liver and kidney function tests, weight, and grooming. Thus, we hypothesize that CBP-mediated activities partially compensate for loss of EP300 in untransformed cells.

Fundamentally, degradation of full-length EP300 causes rapid induction of apoptosis in NB cells compared with catalytic inhibition, where induction of apoptosis is a delayed event. In NB, EP300 physically interacts with and controls the expression of the dominant tumor oncoprotein MYCN. Degradation of EP300 results in rapid loss of MYCN expression and indeed loss of MYCN-driven transcriptional activity. This is associated with apoptosis, although reexpression of MYCN is insufficient to fully blunt the response to EP300 degradation. We hypothesize that rapid degradation of EP300 may cause disruption of protein complexes that are required to sustain the malignant phenotype. Future study will aim to evaluate the precise mechanisms resulting in apoptosis driven by acute degradation or prolonged inhibition of EP300.

Thus, here we identify distinct roles for EP300 and CBP in the regulation of cell growth in high-risk pediatric NB. These findings are similarly identified in a variety of other tumor types, indicating that enhanced dependency on EP300 is a common finding in human cancers. EP300, but not CBP, is required for regulation of H3K27ac and the gene expression landscape of a subset of high-risk NB. This function is promoted by interactions between EP300 and the novel CRC TF TFAP2 β that mediates EP300 binding to enhancers and promoters associated with the CRC. In doing so, TFAP2 β and EP300 collaborate with the CRC to determine gene expression patterns in the adrenergic subtype of high-risk NB. We have capitalized on these findings by generating a novel PROTAC compound, JQAD1, which preferentially depletes full-length EP300 *in vitro* and *in vivo* with limited toxicity to normal tissues. Importantly, EP300 degradation results in loss of the dominant NB oncoprotein MYCN, suppression of CRC-based transcription, and apoptosis. This tool compound will be further optimized to improve solubility and its ability to induce NB cell apoptosis *in vivo*. These data provide key insights into enhancer control in high-risk NB and highlight a novel paradigm for chemical epigenetic control of gene enhancers and mRNA expression in high-risk NB, with implications for other types of human cancers.

METHODS

Material and Data Availability

Requests for resources and reagents should be directed to Dr. Jun Qi (jun_qi@dfci.harvard.edu).

RNA-seq, CUT&RUN, and ChIP-seq data have been deposited in the Gene Expression Omnibus (GEO) database under SuperSeries accession number GSE159617. Code used in this study is described in the experimental details and is available upon request.

Cell Lines

Cell lines were obtained from the ATCC (BE2C, CHP212, IMR32, SKNSH, SHSY5Y, SKNAS, 293T), European Collection of Authenticated Cell Cultures (NB69, CHP134), and DSMZ (Kelly, NGP, SIMA, MHHNB11, NBL-S, SHEP). Cell lines were gifted for this study by Dr. Michael Dyer (St. Jude Children's Research Hospital—NBS, NB1691, SKNMM, and CHLA90), the Cancer Cell Line Factory (Broad Institute—CCLF_PEDS_0046_N primary human fibroblasts), and Dr. Karen Adelman (Harvard Medical School—S2). RRDs included CVCL_0529, CVCL_1125, CVCL_0346, CVCL_0531, CVCL_0019, CVCL_1700, CVCL_0063, CVCL_1448, CVCL_1124, CVCL_2092, CVCL_2141, CVCL_1695, CVCL_1412, CVCL_2136, CVCL_0524, CVCL_8822, CVCL_5628, CVCL_6610, and CVCL_Z232. Cell lines used for the exome-scale CRISPR-Cas9 screen and PRISM analyses have been previously described (30, 47). All cell lines were short tandem repeat (STR)-tested for identity prior to use. Human cell lines were cultured in RPMI media containing 10% heat-inactivated FBS and 1% penicillin-streptomycin. CCLF_PEDS_0046_N primary human fibroblasts were grown in DMEM containing 10% heat-inactivated FBS and 1% penicillin-streptomycin and used between passages 8 and 12. S2 cells were cultured in Schneider media containing 10% heat-inactivated FBS and 1% penicillin-streptomycin. All cell lines were routinely validated to be free of *Mycoplasma* species and used within 10 passages after thawing.

Chemicals

C646 and CBP30 were obtained from Tocris Biosciences. Bortezomib, MLN4924, and thalidomide were obtained from Sigma-Aldrich, and pomalidomide and lenalidomide were obtained from Target Molecule Corp. All other chemicals were synthesized and characterized in the Qi Lab. Compound JQAD1 and Biotin-JQAD1 were designed and synthesized on the basis of the scheme listed in the supporting information. Compound structure and purity were confirmed by nuclear magnetic resonance and LC/MS.

Animals

Eight-week-old female NOD.Cg-Prkdc^{scid} Il2rg^{tm1Wjl}/SzJ (NSG) mice (The Jackson Laboratory, RRID:IMSR_JAX:025216) were used for tumor xenograft studies. For MTD testing, C57BL/6-Crtn^{tm1.1ble}/J (The Jackson Laboratory, RRID:IMSR_JAX:032487) and Crl:CD1(ICR) mice (Charles River Laboratories, RRID:IMSR_CRL:022) were used.

Lentiviral Infection

Stable and inducible Cas9-expressing cell lines were generated using lentiviral particles produced in 293T cells. Briefly, lentiCas9, pCW-Cas9-Blast, pLKO.5-EGFP, pLC-zsGreen, and pLC-CRBN plasmids were obtained from Addgene (RRIDs: Addgene_52962, Addgene_83481, Addgene_57822, Addgene_124301, Addgene_124303). Lentiviruses encoding MYCN or EGFP with in-frame nuclear localization sequences were synthesized by Vectorbuilder Inc. Plasmids were transfected using Lipofectamine 2000 (Invitrogen) along with pMD2.G (Addgene_12259) and psPAX2 (Addgene_12260) into 293T cells to generate viral particles by standard methodologies. sgRNAs targeting individual genes were subcloned by standard methodologies within pLKO.5-EGFP. sgRNA sequences are found in the Supplementary Methods. Kelly, SIMA, BE2C, and NGP cells were infected with lentiCas9 or pCW-Cas9 followed by blasticidin selection. Stable or doxycycline-inducible expression of Cas9 was established by Western blotting of protein lysates using Cas9 antibody (RRID:AB_2750916). Following infection of pLKO.5-EGFP-sgRNA lentivirus, cells were cultured for more than 5 days prior to

evaluation as noted in the figure legend. BE2C cells were infected with pLC-zsGreen or pLC-CRBN lentiviruses and selected using 500 µg/mL hygromycin (Invitrogen). Kelly cells were infected with pLV-EGFP or pLV-MYCN lentiviruses and selected with 5 µg/mL blasticidin (Invitrogen).

Cell Growth Assays

Cells were infected with lentiviruses encoding sgRNAs or treated with compounds as described. Colony assays were performed by replating cells at 500 cells per well in 6-well dishes and grown in regular growth media for 10 days before 100% methanol fixation, 0.05% crystal violet staining, and subsequent quantitation. The CellTiter-Glo assay was performed as per the manufacturer's instructions (Promega). Briefly, 1,000 cells per well were plated into 96-well plates and treated with a range of compound concentrations. Cell viability was measured at the noted time points based on luminescence by the CellTiter-Glo assay (Promega) and read on an Envision 2104 (PerkinElmer) according to the manufacturer's protocol.

Cell-Cycle Analysis

Cells were treated as noted and then resuspended in hypotonic citrate-PI solution for 30 minutes at 37°C, with nuclei stabilized in 5 mol/L NaCl, and then analyzed on a FACSaria II (BD Biosciences) as described in ref. 57. Analysis was performed using FlowJo v10.7 (BD Biosciences).

Western Blotting, Immunoprecipitation, and Proteomic Analyses

Cells growing in culture were lysed for whole-cell lysates as described previously (9, 35). Nuclear lysates were prepared using the NE-PER nuclear lysate kit (Thermo Fisher Scientific) according to the manufacturer's protocol. Chromatin lysates were prepared with the total histone extraction kit (Epigentek). Briefly, equivalent amounts of protein were resolved by Western blotting using 4% to 12% Bis-Tris NuPAGE gels (Thermo Fisher Scientific) prior to transfer and immunoblotting using primary antibodies to MYCN, total H3, CBP, Cas9, cleaved PARP1, cleaved caspase 3, β-actin, TFAP2β, CRBN, H3K27ac, EP300, GATA3, vinculin, and HAND2 (Santa Cruz Biotechnology; RRDs: RRID:AB_2800038, RRID:AB_2756816, RRID:AB_2616020, RRID:AB_2750916, RRID:AB_2160739, RRID:AB_2341188, RRID:AB_330288, RRID:AB_2058198, RRID:AB_2799810, RRID:AB_2118291, RRID:AB_297224, RRID:AB_11212253, and RRID:AB_309711). Secondary antibodies were horseradish peroxidase-conjugated anti-rabbit or anti-mouse (Santa Cruz Biotechnology), incubated prior to exposure to enhanced chemiluminescence reagents (GE Amersham). For immunoprecipitation, equal amounts of protein were diluted in buffer C as described previously (58), and incubated with antibodies covalently conjugated to dynabeads M-270 beads (Thermo Fisher Scientific) overnight according to the manufacturer's instructions. The following antibodies were used: H3K27ac, EP300, CBP, TFAP2β, MYCN, rabbit IgG. The following RRDs were used: RRID:AB_2118291, RRID:AB_297224, RRID:AB_2616020, RRID:AB_2058198, RRID:AB_2800038, and RRID:AB_737197. Immunoprecipitated protein was isolated as per the manufacturer's instructions and subjected to Western blotting or mass spectrometry.

SILAC and H3K27ac Co-IP Mass Spectrometry

For analysis of JQAD1 effects on the nuclear proteome, Kelly cells were labeled with both heavy ¹³C₆ ¹⁵N₂ L-lysine and ¹³C₆ ¹⁵N₄ L-arginine (heavy-labeled cells) or normal L-lysine and L-arginine (light-labeled cells). Heavy-labeled cells were treated with 1 µmol/L JQAD1, and light-labeled cells were treated with equivalent concentrations of DMSO for 24 hours prior to preparation of nuclear lysates using the NE-PER Nuclear Lysis Kit (Thermo Fisher Scientific). Detailed SILAC methods can be found in the Supplementary Methods. Combined heavy and light nuclear lysate was pooled and subjected to trichloroacetic acid

precipitation by standard methodologies, followed by SDS-PAGE. Gel pieces were processed using an LTQ Orbitrap Velos Pro Ion-Trap Mass Spectrometer (Thermo Fisher Scientific). Peptide sequences and protein identity were determined using Sequest (Thermo Fisher Scientific; ref. 59). Protein abundance was determined by Student *t* test comparing 0-hour abundance to 24-hour abundance.

For co-IP/mass spectrometry analysis of H3K27ac, BE2C and Kelly cells were treated to collect nuclear lysates as above. Equal amounts of nuclear protein were immunoprecipitated using Dynabeads M270 magnetic beads covalently bound with H3K27ac antibody (Abcam) or normal rabbit IgG (Santa Cruz Biotechnology) for more than 16 hours at 4°C, prior to washing and elution of immunoprecipitated protein as per the manufacturer's instructions (Invitrogen). Eluted protein was trichloroacetic acid-precipitated, trypsin-digested, and subjected to mass spectrometry. Two independent co-IP/mass spectrometry experiments were performed in each of the BE2C and Kelly cells. High confidence proteins ($n = 35$, Supplementary Table S1) were defined as the subset found in both Kelly and BE2C bound to H3K27ac and not to IgG. Gene identities and function were identified by Gene Ontology and PANTHER analyses (60, 61).

In Vivo Studies

We adhered to animal protocols approved by the Dana-Farber Cancer Institute Animal Care and Use Committee (IACUC). Animals were maintained according to institutional guidelines, and animal experiments approved by local IACUC. For toxicity studies, four female CD1 mice (Charles River Laboratories) were injected i.p. with single doses of 10 mg/kg (R,S)-JQAD1 solubilized in 10% hydroxypropyl β -cyclodextrin (Sigma-Aldrich) in sterile water. Blood concentration of (R,S)-JQAD1 was measured by serial measurements of serum at time points to 24 hours by LC/MS-MS. Pharmacokinetics were performed at ChemPartner using an LC/MS-MS method, and pharmacokinetics parameters were calculated with WinNonlin V 6.2 statistics software (Pharsight Corporation) using a noncompartmental model. For MTD testing, six female CD1 mice were treated with daily i.p. doses of (R,S)-JQAD1 at 10, 20, or 40 mg/kg. Animals were monitored for animal weight, grooming, and behavior daily, without noted effects. For MTD testing in humanized *CRBN* knock-in (Balb/c *CRBN*^{MLE391VAL}; Jackson Laboratories), six mice per treatment group were treated with either vehicle control or (R,S)-JQAD1 at 40 mg/kg/day by i.p. injection. Animal weights, behavior, and grooming were monitored daily for a total of 21 days. At day 14, three mice per treatment group were sacrificed and tissues were fixed for IHC. At this time, blood samples were obtained by retro-orbital puncture and blood analyzed at the Small Animal Imaging Facility at Beth Israel Deaconess Medical Center (Boston, MA) on a Hemavet 9500FS (Drew Scientific) for blood counts, creatinine, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma glutamyl transpeptidase, and blood urea nitrogen measurements.

For tumor studies, 8-week-old female NSG mice (The Jackson Laboratory) were subcutaneously implanted with 2.5×10^6 Kelly cells in 50% Matrigel/PBS. Mice were assigned to two groups: vehicle ($n = 9$) or JQAD1 (40 mg/kg/day; $n = 10$) by i.p. injection. Treatment with small-molecule inhibitors was initiated once tumors engrafted and reached 100 to 150 mm³. Mice were treated for 21 days and then followed for survival. Tumors were measured by calipers and mice were weighed every three days. Animals were euthanized according to institutional guidelines when tumors reached 2,000 mm in length or width or if animals became moribund. Tumor sizes were compared at each time point by two-way ANOVA with *post hoc* Tukey tests. Tumor growth curve kinetics were analyzed by both logistic regression and mixed-effects two-way ANOVA with *post hoc* Tukey tests. Separately, eight animals were xenografted and treated with vehicle ($n = 4$) or JQAD1 ($n = 4$) at 40 mg/kg i.p. daily for 14 days. Animals

were sacrificed at day 14, with tumor being extracted and divided for IHC or RNA-seq analysis.

IHC

IHC was performed on the Leica Bond III automated staining platform. EP300 antibody (RRID:AB_2800077) was run at 1:50 dilution using the Leica Biosystems Refine Detection Kit with citrate antigen retrieval. KAT3A/CBP antibody (RRID: AB_303342) was run at 1:200 using the Leica Biosystems Refine Detection Kit with EDTA antigen retrieval.

RNA-seq and Analyses

Total RNA was extracted from control, A485- or JQAD1-treated Kelly cells using TRIzol (Ambion). Prior to extraction, exogenous spike-in of synthetic ERCC RNA controls were added on the basis of cell number (Ambion). DNase I-treated samples were subjected to library construction with poly-adenylation preparation and sequencing using the Illumina NextSeq 500 (paired end, 75-bp reads).

RNA-seq reads were aligned to a reference index (hg19 revision of the human reference genome), quantified comparing to ERCC spike-in probes, and converted to transcripts per million (TPM). ERCC-normalized expression of each gene after 24 hours of either A485 or JQAD1 treatment was compared against its expression in DMSO-treated samples to create twofold changes. These data were then analyzed by GSEA (RRID:SCR_003199) using the Gene Ontology hallmarks collection in MSigDB (61, 62).

For *in vivo* analyses, purified RNA samples were subjected to library construction with a low input RNA protocol, followed by poly-adenylation preparation and sequencing using the Illumina NextSeq 500 (paired end, 75-bp reads). TPM were calculated as above. Genes were annotated as either controlled by super-enhancers ($n = 671$) or typical enhancers ($n = 27,116$) using H3K27ac data derived from refs. 9, 35, and 63. For "TF" annotations, the list of 1,639 high-confidence human TFs was obtained from ref. 1. Data were compared by ANOVA with multiple hypothesis testing using the original method of Benjamini and Hochberg comparing ERCC-controlled RNA-seq expression in JQAD1-treated samples against vehicle-treated controls. GSEA was performed as above.

Biotin-JQAD1 Pulldown Assays

Biotin-JQAD1 (Supplementary Methods) was added to 500 μ g of whole Kelly cell lysate prepared in IP lysis buffer (Pierce Biotechnology) and incubated for 16 hours at 4°C with end-over-end mixing. High-capacity streptavidin agarose resin (Pierce Biotechnology) was washed three times with cold PBS prior to addition of cell lysate. Lysate was incubated at room temperature for 10 minutes prior to centrifugation, washing, and eluting in NuPAGE LDS sample buffer with reducing agent (Thermo Fisher Scientific). Samples were processed by SDS-PAGE and blotted as above.

AlphaLISA Assay

Assays were performed with minimal modifications from the manufacturer's protocol (PerkinElmer). Briefly, *CRBN*-DDB1 (50 nmol/L), Ni-coated Acceptor Beads (20 μ g/mL), and biotinylated pomalidomide (15 nmol/L) were incubated with 100 nL of compound in 384-well plates (AlphaPlate-384, PerkinElmer) using a Janus Workstation (PerkinElmer). Streptavidin-coated donor beads (20 μ g/mL) were added, incubated at room temperature for one hour, and read on an Envision 2104 (PerkinElmer), as per the manufacturer's protocol.

Genome-Wide Occupancy Analysis

ChIP-seq was performed as described previously (9). The following antibodies for ChIP-seq were used: EP300, CBP, TFAP2 β , ASCL1, and H3K27ac (RRIDs: AB_297224, AB_2616020, AB_2058198,

AB_10918561, AB_2118291). Illumina sequencing, library construction, and ChIP-seq analysis methods have been previously described (51, 58). Remaining ChIP-seq and Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) data were extracted from previously published datasets (GSE120074, GSE94822, GSE65664) available through the GEO portal (<https://www.ncbi.nlm.nih.gov/gds>). For experiments involving analysis of quantitative changes in H3K27ac, pellets of NB cells were spiked in with similarly fixed and processed S2 cells at 1:10 ratio prior to sonication.

ChIP-seq-Enriched Regions and Heat Map Analysis

Regions enriched in ChIP-seq signal were identified using MACS 1.4.2 (RRID:SCR_013291) with corresponding control and parameters `-keep-dup = auto` and `-p 1e-9`. Scatter plots in Fig. 2B and Supplementary Fig. S2A were created from the collapsed union of EP300- and CBP-bound sites, while regions displayed in Fig. 2C and Supplementary Fig. S2B were created from the collapsed union of master TF (HAND2, ISL1, PHOX2B, GATA3, TBX2, ASCL1, TFAP2 β) peaks from the respective cell line. ChIP-seq and ATAC-seq signal was quantified for heat map display in 4-kb windows centered on the middle of each collapsed peak using bamToGFF (<https://github.com/BradnerLab/pipeline/>) with parameters `-m 50 -r -f 1`. Putative PCR duplicates were removed using samtools (RRID:SCR_002105). Rows were ordered by EP300 signal in the whole displayed window (Fig. 2C; Supplementary Fig. S2B).

ChIP-RX Alignment and Processing

ChIP-RX reads from Kelly cells treated with DMSO or 500 nmol/L JQAD1 were aligned the dm6 revision of the *D. melanogaster* reference genome with `-k 1 -chunkmbs 256 -best` to identify spiked-in DNA. Counts of fly reads were determined by counting unique read names in the aligned read file. Remaining non-fly reads were aligned to the hg19 revision of the human reference genome with parameters `-k 2 -m 2 -chunkmbs 256 -best -l 75`. Visualization files were constructed using macs 1.4 with parameters `-w -S -space = 50 -nomodel -shiftsize = 200` to generate wiggle files, which were subsequently normalized by the millions of fly-mapped reads in the corresponding sample.

Super-Enhancer and Typical Enhancer Identification and Assignment

Super-enhancers in Kelly xenografts were identified using ROSE (RRID:SCR_017390), and the single-end BAMs were generated as described previously (58). The collapsed union of regions called using both MACS parameter sets that do not contact the *MYCN*-proximal region were used as input for ROSE (https://bitbucket.org/young_computation/rose), as described in Mansour and colleagues (58) with modifications. H3K27ac peaks were stitched computationally if they were within 12,500 bp of each other, although peaks fully contained within $\pm 2,000$ bp from a RefSeq promoter were excluded from stitching. Stitched enhancers (typical enhancers and super-enhancers) were assigned to the single active gene whose transcription start site is nearest the center of the stitched enhancer.

CUT&RUN Sequencing

CUT&RUN sequencing was performed by standard methodology and using reagents from Epicpyher Inc. H3K27ac (RRID: AB_2893037, Millipore) and IgG (Epicpyher) CUT&RUN validated antibodies were used. Briefly, 500,000 live cells per sample were permeabilized and processed by CUT&RUN by standard protocols. Samples were internally controlled by spiking in exogenous *E.coli* DNA relative to cell number as per the manufacturer's protocol. Libraries were prepared using the Kapa HyperPlus Kit (Kapa Biosciences) and sequenced on a NovaSeq 6000 with 10 million paired-end 75-bp

reads per sample. Reads were aligned to the NC_008253.1 version of the *E. coli* reference genome using bowtie v1.2.2 (RRID:SCR_005476) in single-end mode with parameter `-k 1 -best`. Reads not aligned to *E. coli* were retained and aligned to the hg19 revision of the human reference genome using bowtie v1.2.2 in single-end mode with parameters `-k 2 -m 2 -best`. Mapped human reads were combined and used for H3K27ac peak-calling using MACS v1.4.1 with corresponding IgG control and `-p 1e-9`. Values were normalized by dividing each calculated value by the millions of *E. coli*-mapped reads.

Motif Enrichment Analysis

We compared the CBP and EP300 ChIP-seq peaks in Kelly and BE2C cells to remove the peaks bound by both factors. For each cell line, regions uniquely enriched in EP300 or CBP were determined using bedtools intersect `-v -f 0.5 -r`, which filters regions sharing 50% or more between factors. In each subset, we performed a motif enrichment analysis as previously (64). We quantified TF motif enrichment by using a well-established area under the receiver operator curve (AUROC)-based metric that assesses the presence of a TF motif among the 500 highest confidence peaks (foreground set) as compared with a background set of sequences (65). For the AUROC quantification, we used tools described for the analysis of TF ChIP-seq data from <http://thebrain.bwh.harvard.edu/glossary-GENRE/download.html> (64), which included the use of the R-function "matchPWM" [R-package "Biostrings" (RRID:SCR_016949)] to score each PWM against each sequence and the evaluation of a P_{adj} value to ensure statistical significance. In both cell lines, TFAP2 β (PWM M5912_1 from CIS-BP Database Version 1.02) was the only PWM that showed a relevant differential enrichment, namely an enrichment above 0.6 AUROC ($P < 0.001$) in EP300 unique peaks, and no enrichment (AUROC ~ 0.5 , $P > 0.1$) in CBP unique peaks.

PRISM Screening

PRISM barcoded pooled screening was performed using JQAD1 in 578 barcoded cell lines as described previously (47, 66). Some cell lines included in the screen were genetically engineered to express exogenous genes, and these cell lines were removed, yielding 557 cell lines. Cells in pools of 20 to 25 were thawed and plated into 384-well plates (1,250 cells/well for adherent cell pools; 2,000 cells/well for suspension or mixed suspension/adherent cell pools) containing compound (top concentration: 10 μ mol/L, 8-point, 3-fold dilutions). All conditions were tested in triplicate. Cells were lysed after 5 days of treatment and mRNA-based Luminex detection of barcode abundance from lysates was carried out as described previously (47). Luminex median fluorescence intensity (MFI) data was input to a standard R pipeline (https://github.com/broadinstitute/prism_data_processing) to generate viability estimates relative to vehicle treatment for each cell line and treatment condition, and to fit dose-response curves from viability data.

STRING Database Analysis

NB-specific genetic dependencies ($n = 146$) were identified previously (9), intersected with the Gene Ontology term "Cellular Component - nucleus," and input into the String database (RRID:SCR_005223; ref. 34) to generate interaction plots. Network edges reflect evidence of interactions. Color indicates commercially available compounds targeting the protein (red = yes) or CRC member (blue).

DepMap Dependency Analysis

Analysis of dependency data was retrieved from the DepMap portal (www.depmap.org) using the 20Q2 dataset. Dependency data were extracted as probability of dependency for all cell lines

($n = 757$) for EP300 and CBP. Details of individual cell lines are available at www.depmap.org, and further analysis is described in the Supplementary Methods.

Public Expression Analysis

Analyses of publicly available expression datasets were performed using either the R2 database (<https://hgserver1.amc.nl/cgi-bin/r2/main.cgi#>) or the DepMap portal (www.depmap.org). CCLE analyses of RNA expression and proteomic expression were performed using the 20Q1 data release (67, 68).

Quantification and Statistical Analyses

Data from ChIP-seq, CUT&RUN, and CRISPR-Cas9 screens were analyzed as described previously. Animal experiments were analyzed by mixed-effects modeling and two-sided ANOVA for tumor volume and weight means, and by the log-rank test for survival. Other data were analyzed with one- or two-sided ANOVA with *post hoc* Tukey tests, two-sided *t* tests, or one- or two-sided Fisher exact tests as appropriate for multiple or pairwise comparisons. Statistical significance was defined as $P < 0.05$ unless otherwise stated. Data were analyzed with GraphPad Prism 7.01, and all error bars represent SD unless otherwise noted.

Authors' Disclosures

A.D. Durbin reports grants from the NCI (K08-CA245251, P30-CA021765), the Damon Runyon Cancer Research Foundation (DRSG-24-18), The Rally Foundation for Childhood Cancer Research, CureSearch for Children's Cancer, Alex's Lemonade Stand Foundation, and American Syrian Lebanese Associated Charities during the conduct of the study, as well as a patent for PCT/US2019/059401 issued to Dana-Farber Cancer Institute. N.V. Dharia reports grants from St. Baldrick's Foundation Julia's Legacy of Hope during the conduct of the study, as well as other support from Genentech, Inc. outside the submitted work. O. Wiest reports occasional consults in the general area of computational studies of epigenetic modulators. M.L. Bulyk reports a grant from the NIH/National Human Genome Research Institute (R01-HG010501). B.J. Abraham reports grants from American Lebanese Syrian Associated Charities, including the Collaborative Research Consortium on Cohesin, CTCF, and the 3D Regulatory Nuclear Landscape of Pediatric Cancer Cells, during the conduct of the study; a patent for super-enhancers and methods and uses thereof issued, licensed, and with royalties paid from Syros Pharmaceuticals; and is a shareholder in Syros Pharmaceuticals. K. Stegmaier reports grants from the NCI and the National Institute of Neurological Disorders and Stroke during the conduct of the study, as well as personal fees from AstraZeneca and KronosBio, grants from Novartis, and personal fees and other support from Auron Therapeutics outside the submitted work. J. Qi reports grants from Alex's Lemonade Stand Foundation during the conduct of the study; other support from Epiphany and Talus outside the submitted work; and a patent for acetylation writer inhibitor development and uses thereof pending and a patent for EP300 degrader and uses thereof in neuroblastoma pending. No disclosures were reported by the other authors.

Authors' Contributions

A.D. Durbin: Conceptualization, resources, data curation, formal analysis, supervision, funding acquisition, validation, investigation, visualization, methodology, writing—original draft, project administration, writing—review and editing. **T. Wang:** Formal analysis, validation, investigation, methodology, writing—review and editing. **V.K. Wimalasena:** Validation, investigation, methodology, writing—review and editing. **M.W. Zimmerman:** Conceptualization,

formal analysis, validation, investigation, writing—review and editing. **D. Li:** Validation, investigation. **N.V. Dharia:** Formal analysis, investigation. **L. Mariani:** Formal analysis, investigation, visualization. **N.A.M. Shendy:** Formal analysis, validation, investigation. **S. Nance:** Validation, investigation. **A.G. Patel:** Data curation, investigation. **Y. Shao:** Formal analysis, investigation. **M. Mundada:** Formal analysis, investigation. **L. Maxham:** Investigation. **P.M.C. Park:** Formal analysis, validation, investigation. **L.H. Sigua:** Formal analysis, validation, investigation. **K. Morita:** Resources, investigation. **A.S. Conway:** Validation, investigation. **A.L. Robichaud:** Validation, investigation. **A.R. Perez-Atayde:** Formal analysis, validation, investigation, writing—review and editing. **M.J. Bikowitz:** Validation, investigation, visualization. **T.R. Quinn:** Validation, investigation. **O. Wiest:** Formal analysis, supervision, validation. **J. Easton:** Formal analysis, supervision, investigation. **E. Schonbrunn:** Data curation, supervision, validation, investigation, visualization, writing—review and editing. **M.L. Bulyk:** Resources, data curation, software, investigation. **B.J. Abraham:** Conceptualization, resources, data curation, software, formal analysis, validation, investigation, methodology, writing—original draft, writing—review and editing. **K. Stegmaier:** Conceptualization, resources, data curation, formal analysis, supervision, funding acquisition, project administration, writing—review and editing. **A.T. Look:** Conceptualization, resources, supervision, funding acquisition, project administration, writing—review and editing. **J. Qi:** Conceptualization, resources, data curation, formal analysis, supervision, funding acquisition, validation, investigation, visualization, methodology, writing—original draft, project administration, writing—review and editing.

Acknowledgments

We thank Dr. Richard A. Young (Whitehead Institute, MIT) and Dr. Stuart Orkin (Dana-Farber Cancer Institute) for critical discussion. We thank Dr. Ross Tomaino of the Taplin Mass Spectrometry Facility at Harvard Medical School for assistance with mass spectrometry, and Drs. Jennifer Roth, Ginevra Botta and, Andrew Boghossian of the PRISM screening group at the Broad Institute for assistance with analysis of PRISM data. We thank the Animal Resources Facility and Lurie Family Imaging Center at Dana-Farber Cancer Institute for assistance with animal studies. This work was supported by NIH grants R35-CA210064 (to A.T. Look), R35-CA210030 (to K. Stegmaier), R01-NS088355 (to K. Stegmaier), P01 CA217959 (to K. Stegmaier), P01-CA066996-19 (to J. Qi), K08-CA245251 (to A.D. Durbin), R21-HG009268 (to M.L. Bulyk), T32-CA136432 (to N.V. Dharia), R25-CA23944 (to M. Mundada), P30-CA021765 (St. Jude Comprehensive Cancer Center), and R01-HG010501 (to M.L. Bulyk). This work was supported by the Joey O'Neill Fund. A.D. Durbin was supported by the Damon Runyon Cancer Research Foundation (DRSG-24-18) and is the recipient of funds from the Rally Foundation for Childhood Cancer Research and the CureSearch for Children's Cancer Foundation. A.D. Durbin, M.W. Zimmerman, and J. Qi are supported by funding from Alex's Lemonade Stand Foundation for Childhood Cancer. M.W. Zimmerman was supported by grants from the Charles A. King Trust and Claudia Adams Barr Program. N.V. Dharia was supported by the Julia's Legacy of Hope St. Baldrick's Foundation Fellowship. B.J. Abraham, J. Easton, and A.D. Durbin are supported by the American Lebanese Syrian Associated Charities (ALSAC).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received March 25, 2021; revised August 25, 2021; accepted November 8, 2021; published first November 12, 2021.

REFERENCES

- Lambert SA, Jolma A, Campitelli LF, Das PK, Yin Y, Albu M, et al. The human transcription factors. *Cell* 2018;175:598–9.
- Bradner JE, Hnisz D, Young RA. Transcriptional addiction in cancer. *Cell* 2017;168:629–43.
- Hnisz D, Schuijers J, Lin CY, Weintraub AS, Abraham BJ, Lee TI, et al. Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers. *Mol Cell* 2015;58:362–70.
- Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. *Cell* 2013;153:307–19.
- Lin CY, Lovén J, Rahl PB, Paranal RM, Burge CB, Bradner JE, et al. Transcriptional amplification in tumor cells with elevated c-Myc. *Cell* 2012;151:56–67.
- Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W, et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. *Cell* 2012;151:68–79.
- Grobner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, et al. The landscape of genomic alterations across childhood cancers. *Nature* 2018;555:321–7.
- Ma X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, et al. Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. *Nature* 2018;555:371–6.
- Durbin AD, Zimmerman MW, Dharia NV, Abraham BJ, Iniguez AB, Weichert-Leahey N, et al. Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry. *Nat Genet* 2018;50:1240–6.
- Parker SC, Stitzel ML, Taylor DL, Orozco JM, Erdos MR, Akiyama JA, et al. Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants. *Proc Natl Acad Sci U S A* 2013;110:17921–6.
- Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-André V, Sigova AA, et al. Super-enhancers in the control of cell identity and disease. *Cell* 2013;155:934–47.
- Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. *Cell* 1996;87:953–9.
- Dancy BM, Cole PA. Protein lysine acetylation by p300/CBP. *Chem Rev* 2015;115:2419–52.
- Arany Z, Sellers WR, Livingston DM, Eckner R. E1A-associated p300 and CREB-associated CBP belong to a conserved family of coactivators. *Cell* 1994;77:799–800.
- Weinert BT, Narita T, Satpathy S, Srinivasan B, Hansen BK, Scholz C, et al. Time-resolved analysis reveals rapid dynamics and broad scope of the CBP/p300 acetylome. *Cell* 2018;174:231–44.
- Hammitzsch A, Tallant C, Fedorov O, O'Mahony A, Brennan PE, Hay DA, et al. CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. *Proc Natl Acad Sci U S A* 2015;112:10768–73.
- Zucconi BE, Luef B, Xu W, Henry RA, Nodelman IM, Bowman GD, et al. Modulation of p300/CBP acetylation of nucleosomes by bromodomain ligand I-CBP112. *Biochemistry* 2016;55:3727–34.
- Lasko LM, Jakob CG, Edalji RP, Qiu W, Montgomery D, Digiammarino EL, et al. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. *Nature* 2017;550:128–32.
- Yan G, Eller MS, Elm C, Larocca CA, Ryu B, Panova IP, et al. Selective inhibition of p300 HAT blocks cell cycle progression, induces cellular senescence, and inhibits the DNA damage response in melanoma cells. *J Invest Dermatol* 2013;133:2444–52.
- Yao TP, Oh SP, Fuchs M, Zhou ND, Ch'ng LE, Newsome D, et al. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. *Cell* 1998;93:361–72.
- Rebel VI, Kung AL, Tanner EA, Yang H, Bronson RT, Livingston DM. Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. *Proc Natl Acad Sci U S A* 2002;99:14789–94.
- Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature* 2012;483:603–7.
- Ogiwara H, Sasaki M, Mitachi T, Oike T, Higuchi S, Tominaga Y, et al. Targeting p300 addiction in CBP-deficient cancers causes synthetic lethality by apoptotic cell death due to abrogation of MYC expression. *Cancer Discov* 2016;6:430–45.
- Martire S, Nguyen J, Sundaresan A, Banaszynski LA. Differential contribution of p300 and CBP to regulatory element acetylation in mESCs. *BMC Mol Cell Biol* 2020;21:55.
- Ramos YF, Hestand MS, Verlaan M, Krabbendam E, Ariyurek Y, van Galen M, et al. Genome-wide assessment of differential roles for p300 and CBP in transcription regulation. *Nucleic Acids Res* 2010;38:5396–408.
- Winter GE, Buckley DL, Paulk J, Roberts JM, Souza A, Dhe-Paganon S, et al. DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. *Science* 2015;348:1376–81.
- Burslem GM, Crews CM. Proteolysis-targeting chimeras as therapeutics and tools for biological discovery. *Cell* 2020;181:102–14.
- Wimalasena VK, Wang T, Sigua LH, Durbin AD, Qi J. Using chemical epigenetics to target cancer. *Mol Cell* 2020;78:1086–95.
- Smith BE, Wang SL, Jaime-Figueroa S, Harbin A, Wang J, Hamman BD, et al. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase. *Nat Commun* 2019;10:131.
- Meyers RM, Bryan JG, McFarland JM, Weir BA, Sizemore AE, Xu H, et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. *Nat Genet* 2017;49:1779–84.
- Zhou X, Edmonson MN, Wilkinson MR, Patel A, Wu G, Liu Y, et al. Exploring genomic alteration in pediatric cancer using ProteinPaint. *Nat Genet* 2016;48:4–6.
- Boeva V, Louis-Brennetot C, Peltier A, Durand S, Pierre-Eugene C, Raynal V, et al. Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries. *Nat Genet* 2017;49:1408–13.
- van Groningen T, Koster J, Valentijn LJ, Zwijnenburg DA, Akogul N, Hasselt NE, et al. Neuroblastoma is composed of two super-enhancer-associated differentiation states. *Nat Genet* 2017;49:1261–6.
- Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. *Nucleic Acids Res* 2015;43(Database issue):D447–52.
- Wang L, Tan TK, Durbin AD, Zimmerman MW, Abraham BJ, Tan SH, et al. ASCL1 is activated by LMO1 and MYCN as a core regulatory circuitry member in neuroblastoma. *Nat Commun* 2019;10:5622.
- Song CZ, Keller K, Chen Y, Murata K, Stamatoyannopoulos G. Transcription coactivator CBP has direct DNA binding activity and stimulates transcription factor DNA binding through small domains. *Biochem Biophys Res Commun* 2002;296:118–24.
- He J, Ye J, Cai Y, Riquelme C, Liu JO, Liu X, et al. Structure of p300 bound to MEF2 on DNA reveals a mechanism of enhanceosome assembly. *Nucleic Acids Res* 2011;39:4464–74.
- Michaelides MR, Kluge A, Patane M, Van Drie JH, Wang C, Hansen TM, et al. Discovery of spiro oxazolidinediones as selective, orally bioavailable inhibitors of p300/CBP histone acetyltransferases. *ACS Med Chem Lett* 2018;9:28–33.
- Yasgar A, Jadhav A, Simeonov A, Coussens NP. AlphaScreen-based assays: ultra-high-throughput screening for small-molecule inhibitors of challenging enzymes and protein-protein interactions. *Methods Mol Biol* 2016;1439:77–98.
- Huang M, Weiss WA. Neuroblastoma and MYCN. *Cold Spring Harb Perspect Med* 2013;3:a014415.
- Gabay M, Li Y, Felsher DW. MYC activation is a hallmark of cancer initiation and maintenance. *Cold Spring Harb Perspect Med* 2014;4:a014241.
- Faiola F, Liu X, Lo S, Pan S, Zhang K, Lyman E, et al. Dual regulation of c-Myc by p300 via acetylation-dependent control of Myc protein turnover and coactivation of Myc-induced transcription. *Mol Cell Biol* 2005;25:10220–34.
- Vervooorts J, Luscher-Firzlauff JM, Rottmann S, Lilischkis R, Walsemann G, Dohmann K, et al. Stimulation of c-MYC transcriptional activity and acetylation by recruitment of the cofactor CBP. *EMBO Rep* 2003;4:484–90.

44. Zhang K, Faiola F, Martinez E. Six lysine residues on c-Myc are direct substrates for acetylation by p300. *Biochem Biophys Res Commun* 2005;336:274–80.
45. Donovan KA, An J, Nowak RP, Yuan JC, Fink EC, Berry BC, et al. Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. *Elife* 2018;7:e38430.
46. Fink EC, McConkey M, Adams DN, Haldar SD, Kennedy JA, Guirguis AA, et al. Crbn (I391V) is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice. *Blood* 2018;132:1535–44.
47. Corsello SM, Nagari RT, Spangler RD, Rossen J, Kocak M, Bryan JG, et al. Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. *Nat Cancer* 2020;1:235–48.
48. Kasper LH, Fukuyama T, Biesen MA, Boussouar F, Tong C, de Pauw A, et al. Conditional knockout mice reveal distinct functions for the global transcriptional coactivators CBP and p300 in T-cell development. *Mol Cell Biol* 2006;26:789–809.
49. Liu Y, Wang L, Predina J, Han R, Beier UH, Wang LC, et al. Inhibition of p300 impairs Foxp3(+) T regulatory cell function and promotes antitumor immunity. *Nat Med* 2013;19:1173–7.
50. Sen P, Lan Y, Li CY, Sidoli S, Donahue G, Dou Z, et al. Histone acetyltransferase p300 induces de novo super-enhancers to drive cellular senescence. *Mol Cell* 2019;73:684–98.
51. Sanda T, Lawton LN, Barrasa MI, Fan ZP, Kohlhammer H, Gutierrez A, et al. Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. *Cancer Cell* 2012;22:209–21.
52. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. *Cell* 2005;122:947–56.
53. Saint-André V, Federation AJ, Lin CY, Abraham BJ, Reddy J, Lee TI, et al. Models of human core transcriptional regulatory circuitries. *Genome Res* 2016;26:385–96.
54. Suzuki HI, Young RA, Sharp PA. Super-enhancer-mediated RNA processing revealed by integrative MicroRNA Network Analysis. *Cell* 2017;168:1000–14.
55. Sabari BR, Dall'Agnese A, Boija A, Klein IA, Coffey EL, Shrinivas K, et al. Coactivator condensation at super-enhancers links phase separation and gene control. *Science* 2018;361:eaar3958.
56. Vannam R, Sayilgan J, Ojeda S, Karakyriakou B, Hu E, Kreuzer J, et al. Targeted degradation of the enhancer lysine acetyltransferases CBP and p300. *Cell Chem Biol* 2021;28:503–14.
57. Tate EH, Wilder ME, Cram LS, Wharton W. A method for staining 3T3 cell nuclei with propidium iodide in hypotonic solution. *Cytometry* 1983;4:211–5.
58. Mansour MR, Abraham BJ, Anders L, Berezovskaya A, Gutierrez A, Durbin AD, et al. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. *Science* 2014;346:1373–7.
59. Eng JK, McCormack AL, Yates JR. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. *J Am Soc Mass Spectrom* 1994;5:976–89.
60. Mi H, Muruganujan A, Casagrande JT, Thomas PD. Large-scale gene function analysis with the PANTHER classification system. *Nat Protoc* 2013;8:1551–66.
61. Gene Ontology C. Gene Ontology Consortium: going forward. *Nucleic Acids Res* 2015;43(Database issue):D1049–56.
62. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* 2005;102:15545–50.
63. Oldridge DA, Wood AC, Weichert-Leahey N, Crimmins I, Sussman R, Winter C, et al. Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism. *Nature* 2015;528:418–21.
64. Mariani L, Weinand K, Vedenko A, Barrera LA, Bulyk ML. Identification of human lineage-specific transcriptional coregulators enabled by a glossary of binding modules and tunable genomic backgrounds. *Cell Syst* 2017;5:187–201.
65. Gordan R, Hartemink AJ, Bulyk ML. Distinguishing direct versus indirect transcription factor-DNA interactions. *Genome Res* 2009;19:2090–100.
66. Corsello SM, Bittker JA, Liu Z, Gould J, McCarren P, Hirschman JE, et al. The Drug Repurposing Hub: a next-generation drug library and information resource. *Nat Med* 2017;23:405–8.
67. Ghandi M, Huang FW, Jane-Valbuena J, Kryukov GV, Lo CC, McDonald ER III, et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. *Nature* 2019;569:503–8.
68. Nusinow DP, Szpyt J, Ghandi M, Rose CM, McDonald ER III, Kalocsay M, et al. Quantitative proteomics of the cancer cell line encyclopedia. *Cell* 2020;180:387–402.
69. Gartlgruber M, Sharma AK, Quintero A, Dreidax D, Jansky S, Park Y, et al. Super enhancers define regulatory subtypes and cell identity in neuroblastoma. *Nat Cancer* 2020;2:114–28.